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Chapter 1. General Introduction 
 
1.1. Protein: function, structure, and application 
Proteins express many of the phenomena of living systems, such as metabolism, immunity, and 
signal transmission. Compared with other materials, many protein functions are highly selective and precise. 
For example, enzymes are biocatalysts that regulate a variety of chemical reactions with high specificity 
under mild conditions, and antibodies recognize and capture target molecules (antigen) with a high degree of 
specificity. These protein functions are closely related to thei unique three-dimensional structures. Proteins 
consist of one or multiple polypeptide chains composed of 20 types of L-α-amino acid. Many proteins fold 
into their native structure in aqueous solution [1]. Typically, hydrophobic amino acids are buried within the 
interior of the protein and hydrophilic amino acids are exposed to the aqueous medium. The complex folding 
structures of proteins contribute to their specific functions. For example, enzymes have a substrate-binding 
pocket and active site, and antibodies are typically Y-shaped with a disulfide bond between two heavy chains 
and two light chains [2]. 
Charged amino acids are also important factors in protein function. Four types of charged amino 
acid are exposed on the protein surface, i.e., cationic lysine (Lys) and arginine (Arg), and anionic asparagine 
acid (Asp) and glutamic acid (Glu). As charged amino acids are exposed on the protein surface, folding 
protein molecules have a roughly positive or negative charge. The surface charge of a protein is mainly 
determined by the isoelectric point (pI) and pH—when pH < pI, the protein has a positive charge, and vice 
versa. Note that the pI is typically calculated from the amount of amino acids in the protein. These charged 
amino acids play an important role in protein stability and function [3–10]. For example, superoxide 
dismutase (SOD) can take up anionic O2–· toward the active site due to the local cationic amino acid residues, 
resulting in superior catalytic efficiency (kcat/KM ≈ 109 M-1s-1) [3]. 
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Progress in the field of recombinant DNA technology and biotechnology has markedly increased 
the number of proteins available for various research fields, including biology, bioengineering, and 
biomedicine. In particular, there have been great advances in biomedicines, including enzymes and 
antibodies, over the past two decades because of their high target specificity and biocompatibility. At present, 
more than 200 different biomedicines are approved by the US Food and Drug Administration [11], and used 
in the treatment of several diseases, including cancer [12, 13], autoimmune diseases [14], rheumatoid 
arthritis [15], and acute lymphocytic leukemia [16]. In contrast to small molecule drugs, the markets for 
which have remained at the same level due to patent expiration, it is expected that the market for 
biomedicines will grow up continuously in future. 
 
1.2. Challenges in protein handling 
Despite the significant advances in protein production, the application of proteins has been challenging due 
to their intrinsic instability. In general, the native structure of a protein is affected by physical and chemical 
stress in solution, such as heat, pH, pressure, organic solvent, agitation, and proteases, resulting in 
denaturation of its three-dimensional structure. Denaturated proteins not only lose of their functions but also 
irreversibly aggregate because the hydrophobic amino acid residues are exposed to the aqueous medium. The 
formation of protein aggregates is a serious problem for protein handling in various fields, e.g, aggregates of 
therapeutic proteins are generally unacceptable as protein drugs [17]. Methods for stabilization of proteins 
are important to enhance their application. 
 To overcome the problems associated with instability of proteins in solution, various solution 
additives have been used. Proteins can be stabilized by long term storage- and thermal-induced aggregation 
in the presence of solution additives, typically with small molecular weight, such as arginine [18, 19], amino 
acid alkyl esters [20], oligoamine compounds [21–23], sugars [24–26], and detergents [27]. However, high 
concentrations of solution additives are required to suppress inactivation and aggregation of protein. These 
high concentrations of additives frequently lead to high viscosity and cytotoxicity. In addition, most solution 
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additives other than detergents cannot protect against the effects of mechanical stress, such as agitation, 
which is associated with degradation of therapeutic proteins during transport. 
The functionalization of proteins using mutagenesis or chemical modification is another approach 
to enhance their stability and regulate their activities [7–10, 28]. Conjugation of polymers onto the protein 
surface is a promising strategy for this purpose [29–31]. Conjugation of poly(ethylene glycol) (PEG) is the 
most notable strategy for stabilization of therapeutic proteins due to the steric shield of PEG [32–37]. 
Recently, conjugation of functional polymers onto proteins has been shown to provide novel functions, such 
as enhancement of enzyme activity [38] and stilum-responsiveness [39–41]. However, conjugation of 
polymers requires chemical reaction for covalent attachment of the polymer to the protein, which is both 
time-consuming and costly. In addition, the reduction of intrinsic protein activity often occurs with the 
conjugation of polymers.  
 
1.3. Protein-polyelectrolyte complex (PPC) 
Polyelectrolytes, charged polymers, have great potential as alternative protein stabilizing and functionalizing 
agents. The polyelectrolytes interact with complementary charged proteins, resulting in the formation of 
protein-polyelectrolyte complex (PPC). PPC have the following three features: 
 (i) Simple preparation: Complex formation between proteins and polyelectrolytes occurs 
spontaneously because the driving force is non-covalent interaction, such as electrostatic interactions, 
hydrophobic interactions, van der Waals forces, and hydrogen bonds. That is, PPC solutions can be prepared 
by mixing protein and polyelectrolyte solutions without the need for special equipment. Thus, the 
preparation of PPC is easier than that of protein-polymer conjugates, which requires a complex procedure of 
chemical modification. The complementary charge combination should be selected for preparation of PPC, 
i.e., cationic proteins are used with anionic polyelectrolytes, and vice versa. 
 (ii) Various states: PPC can exist in several states depending on a number of facors, such as pH, 
temperature, pressure, ionic strength, stoichiometric ratio, and the types of protien and polyelectrolyte [42, 
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43].	 These states can be roughly classified as soluble PPC and insoluble PPC. Soluble PPC have a surplus 
charge associated with dispersion in aqueous medium and a size of about < 100 nm, while insoluble PPC 
with a size of > 100 nm has less charge. Insoluble PPC frequently self-assemble, resulting in precipitate, 
cocervate, and gel formation [42, 43]. Furthermore, novel types of PPC have been reported using unique 
polyelectrolytes, including spherical polyelectrolyte brush [44] and polyion complex micelles [45–47]. 
 (iii) Reversibility: PPC are generally reversible because their non-covalent interactions are weaker 
than the covalent interactions of protein-polymer conjugations. For example, the salts at high ionic 
concentration shield the electrostatic interaction between proteins and polyelectrolytes, resulting in 
disruption of PPC [48, 49]. The salt-responsiveness of PPC is generally independent of the state of the PPC. 
Similarly, the reversibility of the PPC has been reported using several methods, including protein [50, 51], 
polyelectrolytes [52–54], and pulse electric field [55]. 
 Although there have been a number of fundamental studies of PPC, they have been used in few 
practical applications. There have been few reports regarding the formation of PPC tailored to achieve on/off 
switching of enzyme activities [53, 54] and thermal stabilization [52]. Recently, the on/off switching of 
enzyme activity using PPC was applied to a sensor array for detection of protein ratio in serum [50, 51]. 
Therefore, the development of a protein handling method using PPC would be useful for elucidating the 
utility of proteins in various fields. 
 
1.4. Objective of this study 
In this study, three protein-handling methods were developed using PPC to facilitate practical application of 
proteins. Chapter 2 descrives a novel soluble PPC with PEGylated polyelectrolyte that can regulate the 
activity of unstable enzymes and stabilize oligomeric protein against stress. Chapter 3 presents an enzyme 
hyperactivation phenomenon that enables enhancement of enzyme activity. Chapter 4 discusses a 
precipitation-redissolution method for preparing high-concentration protein formulations. The last two 
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chapters present an overview and discussion of this research, as well as a discussion of future work to be 
performed. 
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Chapter 2. PEGylated Polyelectrolyte 
 
2.1. Improved Complementary Polymer Pair System: Switching 
for Enzyme Activity by PEGylated Polymers 
 
2.1.1. Introduction 
On/off switching of enzymatic activity holds a great deal of potential for various applications, including 
biosensors, bioreactors, and high performance protein delivery systems. Several attempts have been made to 
regulate enzymatic activity. Strategies typically involve covalent modifications of a ligand [1] and 
stimuli-responsive polymers [2,3] in close proximity to the active site of enzymes. These strategies facilitate 
many potential uses for enzymes because the activities of these modified enzymes can be easily switched by 
appropriate signals, such as heavy metal ions, light, or temperature. On the other hand, noncovalent 
approaches involve the use of artificial reversible inhibitors, such as polymeric substrate analogues,4 
molecular clips and tweezers [5], gold nanoparticles [6−11], and micelles [12−14]. However, these methods 
are still time-consuming and costly. 
Recently, our group have developed a convenient technique, the complementary polymer pair 
system (CPPS), which allows the control of enzymatic activity by a pair of oppositely charged polymers [15−
17]. For example, an enzyme with a cationic surface is inactivated by the addition of an anionic polymer due 
to binding through electrostatic interactions, followed by reactivation of enzyme activity by the addition of a 
cationic polymer. This simple and inexpensive system was applied successfully to several model enzymes, 
such as ribonuclease A, lysozyme, trypsin, and cellulase with cationic poly(allylamine) (PAA) and anionic 
poly(acrylic acid) (PAAc). However, the system could not be used for switching of α-amylase. This failure 
was concluded to be the result of irreversible denaturation of enzymes due to the formation of aggregates 
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between α-amylase and PAA [16]. 
To apply CPPS to enzymes that are liable to undergo aggregate formation, I focused on charged 
polymers modified with poly(ethylene glycol) (PEG), as the modification of PEG (PEGylation) is a 
well-used strategy to avoid aggregate formation of polyion complexes [18−25]. Here, I investigated the 
improved CPPS that allows us to switch the activity of large and unstable anionic enzymes, α-amylase (pI = 
4.2) and β-galactosidase (pI = 5.1) (Figure 2.1.1A), using the designed and synthesized cationic copolymer 
with poly(ethylene glycol) backbone, poly(N,N-diethylaminoethyl methacrylate)-block-poly(ethylene glycol) 
(PEAMA-b-PEG) (Figure 2.1.1B). In contrast to PAA, both enzymes were inactivated by PEAMA-b-PEG 
with the formation of water-dispersed complexes, and subsequently the activity of the enzymes was 
successfully recovered from the complex by the addition of PAAc (Figure 2.1.1C). 
 
 
2.1.2. Materials and Methods 
Materials 
Aspergillus oryzae α-amylase was purchased from Fluka Chemica GmbH (Buchs, Switzerland). Escherichia 
coli β-galactosidase and 3-(N-morpholino)propanesulfonic acid (MOPS) were from Sigma Chemical. Co. (St. 
Louis, MO). p-Nitrophenyl-α-D-maltoside (PNPM), o-nitrophenyl-β-D-galactopyranoside (ONPG), and 
PAAc with an average molecular weight of 5000 were from Wako Pure Chemical Ind., Ltd. (Osaka, Japan). 
PAA with an average molecular weight of 5000 was acquired from Nitto Boseki Co., Ltd. (Fukushima, 
Japan). PEAMA-b-PEG was synthesized as reported previously [26,27]. All chemicals used were of high 
quality analytical grade and were used as received. 
 
Protein Concentration 
Protein concentrations were determined from the absorbance at 280 nm using a spectrophotometer (V-630; 
Jasco Corp., Tokyo, Japan), with extinction coefficients of 106,160 M−1 cm−1 (α-amylase) or 1,046,760 M−1 
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cm−1 (β-galactosidase) [28]. 
 
 
 
Enzyme Assay 
Enzyme assay for α-amylase was performed as follows. A substrate solution of 150 µL containing 1.0 mM 
PNPM and 10 mM MOPS buffer (pH 7.0) was mixed with 150 µL of 4.0 µM α-amylase solution. The initial 
reaction velocities were determined from the slope of the initial increase in the absorbance intensity at 410 
nm. Enzyme assay for β-galactosidase was performed as follows. A substrate solution of 200 µL containing 
 
Figure 2.1.1. (A) Tertiary structures of enzymes (PDB entries: α-amylase, 6TAA; β-galactosidase, 3MUY). (B) 
Chemical structures of polymers. (C) Schematic illustration of improved CPPS. 
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10 mM ONPG and 10 mM MOPS buffer (pH 7.0) was mixed with 100 µL of 23 nM β-galactosidase 
solutions. The initial reaction velocities were determined from the slope of the initial increase in the 
absorbance intensity at 410 nm. 
 
Inactivation of Enzymes by Polymers 
Various concentrations of PEAMA-b-PEG and PAA were added to solutions containing enzymes (4.0 µM 
α-amylase or 23 nM β-galactosidase) and 10 mM MOPS buffer (pH 7.0). After incubation at 25 oC for 2 h 
without shaking, the enzyme activity was measured. PEAMA-b-PEG and PAA have 12 and 70 positive 
charges at pH 7.0, respectively; α-amylase and β-galactosidase have 24 and 149 negative charges at pH 7.0, 
respectively. 
 
Reactivation of Enzymes by PAAc 
Reactivation of enzymes was performed by adding PAAc to enzyme/polymer complex solution. Solutions of 
180 µL containing enzymes (4.0 µM α-amylase or 23 nM β-galactosidase) and 10 mM MOPS buffer (pH 
7.0) were incubated with PEAMA-b-PEG (15 µM for α-amylase or 2.0 µM for β-galactosidase) or PAA (40 
µM for α-amylase or 1.0 µM for β-galactosidase) at 25 oC for 24 h, and then aliquots of 20 µL containing 
various concentrations of PAAc and 10 mM MOPS buffer (pH 7.0) were added to the samples. After 
incubation at 25 oC for 2 h, the samples were centrifuged at 15000g for 15 min at 25 oC. The enzyme activity 
of supernatant was then measured. 
 
Circular Dichroism 
Circular dichroism (CD) experiments were performed in a 1 mm (α-amylase) or 10 mm (β-galactosidase) 
path- length quartz cuvette using a spectropolarimeter (J-720; Jasco Corp). Solutions of 1800 µL containing 
enzymes (4.0 µM α-amylase or 23 nM β-galactosidase) and 10 mM MOPS buffer (pH 7.0) were incubated 
with PEAMA-b-PEG (15 µM for α-amylase or 2.0 µM for β-galactosidase) or PAA (40 µM for α-amylase 
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or 1.0 µM for β-galactosidase) at 25 oC for 24 h, and then aliquots of 200 µL containing PAAc (25 µM for 
α-amylase/PEAMA-b-PEG, 40 µM for α-amylase/PAA, 2.0 µM for β-galactosidase/PEAMA-b-PEG, or 0.3 
µM for β-galactosidase/PAA) and 10 mM MOPS buffer (pH 7.0) were added to the samples. After 
incubation at 25 oC for 2 h, the samples were centrifuged at 15000g for 15 min, and the spectra of 
supernatant were measured at 25 oC. The CD spectra of the samples were corrected by subtracting the 
corresponding spectra of buffers in the absence of enzymes. 
 
Dynamic Light Scattering 
Dynamic light scattering (DLS) experiments were performed using a light scattering photometer (Zetasizer 
Nano ZS; Malvarn Instruments, Worcestershire, UK). The size of enzyme/polymer complexes was 
determined as follows. Solutions containing enzymes (4.0 µM α-amylase or 230 nM β-galactosidase) and 10 
mM MOPS buffer (pH 7.0) were incubated with PEAMA-b-PEG (15 µM for α-amylase or 20 µM for 
β-galactosidase) or PAA (40 µM for α-amylase or 10 µM for β-galactosidase) at 25 oC for 24 h, and then 
DLS measurements were carried out at 25 oC. 
 
 
2.1.3. Results and Discussion 
Inactivation of Enzymes by Polymers 
Previously, our group reported that CPPS failed in on/off switching of α-amylase activity due to the 
formation of aggregates between the anionic enzyme and cationic PAA [16]. To confirm the versatility of 
improved CPPS, on-off swiching experiments for α-amylase and β-galactosidase as a model for large and 
unstable anionic enzymes were compared using newly synthesized PEAMA-b-PEG and previously reported 
PAA. Figure 2.1.2A shows the enzyme activity of α-amylase when 4.0 µM enzyme was mixed with 
PEAMA-b-PEG or PAA. The enzyme activity decreased concomitantly with concentrations of both 
PEAMA-b-PEG and PAA; the enzymatic activity was fully inactivated with addition of 15 µM (3.75 equiv) 
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PEAMA-b-PEG and 40 µM (10 equiv) PAA. Interestingly, the solution containing α-amylase and 
PEAMA-b-PEG was a clear liquid, although addition of PAA caused the formation of visible aggregates. A 
similar pattern of PEAMA-b-PEG and PAA was observed for β-galactosidase (Figure 2.1.2B). The enzyme 
activity of β-galactosidase dropped to almost zero in the presence of 2.0 µM (87 equiv) PEAMA-b-PEG and 
1.0 µM (43 equiv) PAA, while the solutions containing β-galactosidase and both polymers were not turbid. 
These results indicated that cationic polymers bind strongly to the anionic surface of enzymes, resulting in 
full inactivation of the enzymes. 
 
 
 
Reactivation of Enzymes by PAAc 
α-Amylase and β-galactosidase were inactivated by incubation with PEAMA-b-PEG and PAA for 24 h, and 
then the inactivated enzymes were titrated with PAAc. The addition of PAAc to the complex between 4.0 
µM α-amylase and 15 µM PEAMA-b-PEG resulted in 85% recovery of the activity, while the recovery of 
α-amylase inhibited by PAA reached only 10% in the presence of 20 µM PAAc (Figure 2.1.3A). Similarly, 
 
 
Figure 2.1.2. Inactivation of anionic enzymes by cationic polymers. Various concentrations of PEAMA-b-PEG 
(closed circles) or PAA (open circles) were added to solution containing 4.0 µM α-amylase (A) or 23 nM 
β-galactosidase (B). 
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23 nM β-galactosidase inhibited by 2.0 µM PEAMA-b-PEG was fully recovered by the addition of 1.6 µM 
PAAc (Figure 2.1.3B). On the other hand, the addition of PAAc to the solution containing 
β-galactosidase/PAA complexes did not show full recovery of enzyme activity. Therefore, I hypothesized 
that the enzyme inactivation by PEAMA-b-PEG had a favorable effect on the conformation of the enzymes, 
resulting in highly reversible inhibition. 
 
 
 
Secondary Structure of Enzyme/Polymer Complex 
To evaluate the conformational changes in the enzymes, CD spectra of the enzyme/polymer complexes were 
measured (Figure 2.1.4). As anticipated, a slight change was observed in the far-UV CD spectrum of 4.0 µM 
α-amylase with the addition of 15 µM PEAMA-b-PEG (Figure 2.1.4A). In addition, the far-UV CD 
spectrum was maintained after the addition of 25 µM PAAc. Thus, the secondary structure of α-amylase did 
not change significantly in the processes of activity switching by PEAMA-b-PEG and PAAc. In contrast, the 
 
 
Figure 2.1.3. Reactivation of inhibited anionic enzymes by PAAc. Various concentrations of PAAc were added to 
solutions containing 4.0 µM α-amylase and 15 µM PEAMA-b-PEG (closed circles) or 40 µM PAA (open circles) 
(A); 23 nM β-galactosidase and 2.0 µM PEAMA-b-PEG (closed circles) or 1.0 µM PAA (open circles) (B). 
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far-UV CD spectrum of 4.0 µM α-amylase disappeared remarkably with the addition of 40 µM PAA (Figure 
2.1.4B). Although PAAc was added to the solution with α-amylase/PAA complex, the far-UV CD spectrum 
showed less recovery, suggesting that PAA induced a marked conformational change in the secondary 
structure. A similar tendency was observed for β-galactosidase. In contrast to PAA, the far-UV CD spectrum 
of 23 nM β-galactosidase did not change when the enzyme was inactivated by 2.0 µM PEAMA-b-PEG and 
reactivated by 2.0 µM PAAc (Figure 2.1.4C,D). These observations suggested that complex formation 
between PEAMA-b-PEG and both enzymes did not strongly affect the secondary structures of the enzymes. 
Thus, the enzyme inactivation by PEAMA-b-PEG is likely coupled with local structural changes rather than 
complete unfolding. These weak and multiple bindings may result in non-competitive inhibition of the 
enzymatic activity from a kinetic viewpoint [17]. 
 
 
 
 
 
Figure 2.1.4. Far-UV CD spectra of anionic enzymes in the absence or presence of polymers. 4.0 µM α-amylase was 
mixed with 15 µM PEAMA-b-PEG (A) or 40 µM PAA (B), and then PAAc (25 µM for PEAMA-b-PEG, 40 µM for 
PAA) was added to the solutions. 23 nM β-galactosidase was mixed with 2.0 µM PEAMA-b-PEG (C) or 1.0 µM 
PAA (D), and then PAAc (2.0 µM for PEAMA-b-PEG 0.3 µM for PAA) was added to the solutions. Native 
enzymes, solid lines; inactivated enzymes, dotted lines; recovered enzymes, broken lines. 
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Size of Enzyme/Polymer Complex 
It is possible that PEAMA-b-PEG inactivates anionic enzymes with the formation of nonaggregated 
complexes, resulting in a lower degree of enzyme secondary structure disruption. To evaluate this suggestion, 
DLS was used to determine the hydrodynamic radius (Rh) of the complexes between anionic enzymes and 
cationic polymers preincubated for 24 h. Figure 2.1.5 shows a representative result of the particle size 
distribution for α-amylase and β-galactosidase in the absence and presence of cationic polymers. The Rh 
values of α-amylase and β-galactosidase were 5.9 and 13.3 nm, respectively. The addition of 15 µM 
PEAMA-b-PEG to 4.0 µM α-amylase slightly increased Rh to 9.7 nm, whereas the mixture of 4.0 µM 
α-amylase and 40 µM PAA showed Rh ≈ 500 nm, indicating that PAA but not PEAMA-b-PEG formed a 
large aggregate with α-amylase. Likewise, the mixture of 230 nM of β-galactosidase and 20 µM 
PEAMA-b-PEG showed Rh of 47.5 nm, while that with 10 µM PAA showed Rh ≈ 1900 nm. Therefore, It was 
suggested that the PEG segment of PEAMA-b-PEG is crucial for dispersion of the complex between cationic 
PEAMA-b-PEG and anionic enzymes. 
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PEG is a nonionic water-soluble polymer with high flexibility and large excluded volume. 
Therefore, PEG provides the water- dispersed properties for a pair of oppositely charged PEGylated block 
copolymers by the formation of a corona of PEG segments surrounding the core of water-incompatible 
segment [18−25] similar to the present case. DLS measurement revealed that Rh values of α-amylase and 
β-galactosidase with PEAMA-b-PEG were increased by 1.6- and 3.6-fold compared to those in the absence 
of these polymers, respectively (Figure 2.1.5), indicating that PEAMA-b-PEG likely formed micelle-like 
complexes [29] with β-galactosidase but not α-amylase. On the other hand, PAA inactivated anionic 
enzymes with the formation of aggregates due to the lack of a soluble PEG segment, leading to the 
irreversible denaturation of the enzyme. The conformational changes were probably due to the strong 
physical stress between the aggregates of enzyme/PAA complexes. 
 
 
 
Figure 2.1.5. Hydrodynamic radii (Rh) of anionic enzymes in the absence or presence of cationic polymers. 4.0 µM 
α-amylase (A) and 230 nM β-galactosidase (B) were inactivated by PEAMA-b-PEG (15 µM for α-amylase, 20 µM 
for β-galactosidase) or PAA (40 µM for α-amylase, 10 µM for β-galactosidase). None, solid lines; PEAMA-b-PEG, 
dotted lines; PAA, broken lines. 
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2.1.4. Conclusion 
In summary, the novel cationic copolymer PEAMA-b-PEG was developed to establish CPPS for large and 
unstable enzymes. PEAMA-b-PEG successfully inactivated anionic enzymes with the formation of 
water-dispersed complexes. The complexation between PEAMA-b-PEG and enzymes had little influence on 
the conformation of enzymes, and hence the enzyme activity was fully recovered by the addition of anionic 
PAAc. It is expected that cationic unstable and aggregated enzymes would be switched on/off by PEGylated 
anionic polymers. Soluble complex formation between PEGylated charged polymer and enzymes linked to 
fully reversible inactivation of enzymes would expand the potential of enzymes in biomedical and 
biotechnological fields. 
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2.2. Noncovalent PEGylation of L-Asparaginase Using 
PEGylated Polyelectrolyte 
 
2.2.1. Introduction 
Progress in the fields of recombinant technology and biotechnology has markedly increased the numbers of 
therapeutic proteins [1]. Many therapeutic proteins have large and multidomain structures consisting of 
homo- or heteropolypeptide chains. The formation of quaternary structures is required for bioactivity of 
multidomain enzymes, such as tetrameric L-asparaginase (ASNase), tetrameric uricase, and trimeric arginase 
[2]. In comparison with single-domain proteins, multidomain proteins are prone to aggregation and are 
inactivated by common stresses, such as changes in temperature, pH shift, and mechanical stress [3]. 
Aggregation is the most serious problem for therapeutic proteins causing loss of their bioactivities, and 
therefore such aggregates in therapeutic proteins are generally unacceptable [4]. Accordingly, a method for 
stabilization of multidomain proteins is important for pharmaceutics. 
Covalent attachment of polymers to the protein surface is one strategy for stabilization of proteins 
[3,5,6]. Especially, conjugation of poly(ethylene glycol) (PEGylation) is the most promising method for 
protein therapy [7–12]. PEG is a hydrophilic, nonionic, and nontoxic polymer that provides a steric shield for 
proteins, resulting in improvement of the pharmacological properties of the proteins. In addition, PEGylation 
also protects proteins against aggregation and protease digestion in vitro [13–15]. At present, 12 types of 
PEGylated therapeutic protein have been approved by the United States Food and Drug Administration [12], 
and are used for several diseases, such as severe combined immunodeficiency disease, acute lymphoblastic 
leukemia, and refractory chronic gout [11]. However, covalent PEGylation requires chemical reaction for 
conjugation of PEG to proteins, which is both time consuming and costly. 
Noncovalent PEGylation has been suggested as an alternative method for stabilizing proteins using 
 
25 
PEG [16–21]. A common strategy for noncovalent PEGylation involves designing functional PEG 
derivatives that bind to proteins. For example, Mueller et al. [17,18,21] synthesized several PEG derivatives 
conjugated with hydrophobic ligands, which reduced the aggregation of salmon calcitonin and lysozyme. 
Similarly, PEG derivatives conjugated with sugars [19], biotin [16], and nitrilotriacetic acid [20] have also 
been designed. However, there have been few studies regarding noncovalent PEGylation of therapeutic 
proteins. 
PEGylated polyelectrolytes are also PEG derivatives. The polyelectrolyte interacts strongly with 
complementary charged proteins through multiple electrostatic interactions, resulting in the formation of 
various types of protein-polyelectrolyte complex (PPC) [22–28]. I have recently shown that PEGylated 
polyelectrolyte could form a water-soluble PPC with α-amylase and β-galactosidase due to the PEG segment 
of the polyelectrolyte [25]. Here, stabilization of therapeutic protein through noncovalent PEGylation using 
PEGylated polyelectrolytes was investigated. ASNase was selected as a model therapeutic protein which 
used in acute lymphoblastic leukemia. Anionic ASNase and cationic poly(ethylene glycol)-block-poly(N,N- 
dimethylaminoethyl methacrylate) (PEG-b-PAMA) formed a water-soluble PPC with maintenance of the 
original secondary structure and enzyme activity of ASNase. As expected, PEG-b-PAMA protected ASNase 
against protease digestion and shaking-induced inactivation. It is important to note that these protective 
effects of PEG-b-PAMA were comparable to those of commercial PEGylated ASNase (PEG-ASNase). 
 
 
2.2.2. Materials and Methods 
Materials 
L-Asparaginase from Escherichia coli was from Kyowa Hakko Kirin Company Ltd. (Tokyo, Japan). 
Nessler’s reagent, 3-(N-morpholino)propanesulfonic acid (MOPS), poly(ethylene glycol)-L-asparaginase 
(PEG-ASNase) from Escherichia coli, and trypsin from bovine pancreas were from Sigma Chemical 
Company (St. Louis, Missouri). Poly(N,N-dimethylaminoethyl methacrylate) (PAMA) with average 
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molecular weight (Mw) 4.2 kDa, PEG-b-PAMA with average Mw (PEG) 5.0 and Mw (PAMA) 5.5 kDa were 
from Polymer Source Inc. (Dorval, QC, Canada). Ammonium sulfate, L-asparagine (L-Asn), PEG with 
average Mw 7.5 kDa, and trichloroacetic acid (TCA) were from Wako Pure Chemical. Ind., Ltd. (Osaka, 
Japan). Phenylmethyl- sulfonyl fluoride (PMSF) was from Nacalai Tesque (Kyoto, Japan). These chemicals 
were of high-quality analytical grade and were used as received. 
 
Protein Concentrations 
The concentrations of proteins were determined from the absorbance at 280 nm using a spectrophotometer 
(V-630; Japan Spectroscopic Company, Ltd., Tokyo, Japan) with extinction coefficients of 94,020 M−1 cm−1 
(ASNase and PEG-ASNase) or 37,650 M−1 cm−1 (trypsin) [29]. 
 
Dynamic Light Scattering 
Dynamic light scattering (DLS) experiments were performed using a Zetasizer Nano ZS light scattering 
photometer (Malvern Instruments, Worcestershire, UK) equipped with a 4 mW He-Ne ion laser (λ = 633 
nm). The sizes of the protein with polymer were determined as follows. Solutions containing 1.0 µM 
ASNase, 0-100 µM polymers, and 10 mM MOPS buffer (pH 7.0) were placed in a 1-cm path length 
disposable cuvette, and DLS measurements were performed at 25oC at a detection angle of 173o. The 
viscosity of the solutions was approximated by the value of the 10 mM MOPS solution (η = 0.87 cP). All 
results are presented as the averages of three independent experiments. 
 
Circular Dichroism 
Circular dichroism (CD) experiments were performed in a 1-mm path length quartz cuvette using a J-720 
spectropolarimeter (Japan Spectroscopic Company, Ltd.). Solutions containing 1.0 µM ASNase, 0-40 µM 
polymers, and 10 mM MOPS buffer (pH 7.0) were prepared, and the spectra were measured at 25oC. The CD 
spectra of the samples were corrected by subtracting the corresponding spectra of the buffers in the absence 
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of proteins. 
 
Enzyme Assay 
The enzyme activities of ASNase and PEG-ASNase were measured as follows. An aliquot of 50 µL of the 
protein solution was incubated with 950 µL of the substrate solution containing 22 mM L-Asn, 10 mM 
MOPS (pH 7.0) at 37oC for 2.0 min (ASNase) or 10 min (PEG-ASNase). The reaction was stopped by the 
addition of 250 µL of 3.0 M TCA in the assay mixture. Subsequently, the sample was mixed with Nessler’s 
reagent to measure the ammonia released after L-Asn hydrolysis. The absorbance was monitored 
spectrophotometrically at 450 nm. The concentration of ammonia produced by the enzymatic reaction was 
determined from a reference curve using ammonium sulfate as a standard. One unit of enzyme activity was 
defined as the amount of enzyme required to produce 1.0 µmol ammonia per min at 37oC. 
 
Proteolytic Degradation by Trypsin 
Trypsin solution of 1.0 µM was prepared by dissolving the lyophilized trypsin in cold 1.0 mM HCl. An 
aliquot of 5.0 µL of trypsin solution was added to 500 µL protein solutions (ASNase: 1.0 µM ASNase, 0-40 
µM polymers, 10 mM MOPS, pH 7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 10 mM MOPS, pH 7.0) at 37oC. 
After incubation for respective periods, enzyme activities of ASNase were measured by above-mentioned 
assay. 
 
SDS-PAGE 
An aliquot of 5.0 µL of trypsin solution was added to 500 µL protein solutions (ASNase: 1.0 µM ASNase, 
0-40 µM polymers, 10 mM MOPS, pH 7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 10 mM MOPS, pH 7.0) at 
37oC. After incubation for 2.0 h, 5.0 µL of 100 mM PMSF in ethanol was added to stop the trypsin digestion 
reaction. The samples were then mixed with an equal volume of loading buffer containing 4.0% (w/v) SDS, 
20% sucrose, 0.010% (w/v) bromophenol blue, and 125 mM Tris-HCl (pH 6.8). The samples were boiled for 
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15 min followed by loading on a 14% PAGE with a standard ladder marker, which was obtained from 
Bio-Rad Laboratories (Hercules, California). After gel electrophoresis, the gels were stained with silver 
nitrate. 
 
Shaking Treatment 
Aliquots of 1.2 mL of protein solutions (ASNase: 1.0 µM ASNase, 0-40 µM polymers, 10 mM MOPS, pH 
7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 10 mM MOPS, pH 7.0) were added to 2.0 mL microcentrifuge 
tubes (Thermo Scientific, Waltham, Mas- sachusetts). The samples were then shaken at 500 rpm for 0-6 h. 
The enzyme activities and sizes of the samples were measured by the assay described above. 
 
Heat Treatment 
Protein solutions (ASNase: 1.0 µM ASNase, 0-40 µM polymers, 10 mM MOPS, pH 7.0; PEG-ASNase: 1.0 
µM PEG-ASNase, 10 mM MOPS, pH 7.0) were heated at 60oC for 0-2 h. The enzyme activities and sizes of 
the samples were measured by the assay described above. 
 
 
2.2.3. Results 
Preparation and Characterization of ASNase/PEG-b-PAMA Complexes 
Figure 2.2.1A shows the chemical structures of polymers used in this study. Cationic PEG-b-PAMA had 
PEG and PAMA regions with average Mw of 5.0 and 5.5 kDa, respectively. Two types of homopolymer were 
also used for control experiments: cationic PAMA with an average Mw of 4.2 kDa and nonionic PEG with an 
average Mw of 7.5 kDa, which were similar to PEG-b-PAMA. Anionic ASNase, which is used in treatment 
of acute lymphoblastic leukemia, was selected as a multidomain therapeutic protein. 
I demonstrated previously that cationic PEGylated polyelectrolytes bind to anionic proteins, 
resulting in the formation of water-dispersed PPCs [25]. Therefore, a PPC between cationic PEG-b-PAMA 
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and anionic ASNase was prepared, as illustrated in Figure 2.2.1B. Figure 2.2.2A shows the hydrodynamic 
diameter (Dh) of ASNase in the absence or presence of polyelectrolytes. The Dh of ASNase alone was 11.1 
nm, but increased to >1000 nm with the addition of 1.0 µM PEG-b-PAMA. When further PEG-b-PAMA 
was added to ASNase solution, the Dh decreased with increasing concentration of PEG-b-PAMA, and then 
reached a plateau of 22 nm at around 40 µM PEG-b-PAMA. In contrast, the Dh of ASNase increased sharply 
with increasing concentration of cationic PAMA with a plateau of >1000 nm at around 30 µM PAMA. The 
Dh of PEG-b-PAMA and PAMA alone could not be detected by DLS. These results indicated that ASNase 
formed a soluble PPC with PEG-b-PAMA, whereas ASNase formed an aggregative PPC with PAMA. 
 
 
 
 
 
Figure 2.2.1. (A) Chemical structures of polymers. (B) Schematic illustration of PPC with PEG-b-PAMA. Reactivs) 
(B). Figure 1. 
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Figure 2.2.2. Characterization of ASNase/PEG-b-PAMA complexes. (A) Hydrodynamic diameter (Dh) variations of 
the ASNase in the presence of polymers at various [polymer]/[ASNase] ratios. (B) Far-UV CD spectra of ASNase in 
the absence or presence of polymers at [ASNase]/[polymer] = 1:40. (C) Normalized enzyme activity of the ASNase 
in the absence or presence of polymers at [ASNase]/[polymer] = 1:40. 
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Subsequently, the structure and enzyme activity of ASNase in the presence of polymers were 
characterized. Far-UV CD spectra of ASNase in the presence of PEG-b-PAMA and PEG were identical to 
those of the native ASNase, whereas those of ASNase in the presence of PAMA decreased (Figure 2.2.2B). 
These results indicated that PAMA denatured the ASNase in aggregate form, as shown in Figure 2.2.2A. 
Furthermore, PEG-b-PAMA as well as PEG did not affect the enzyme activity of ASNase, whereas it 
decreased in the presence of PAMA (Figure. 2.2.2C). These results indicated that ASNase retained the 
original properties of secondary structure and enzyme activity after the formation of a PPC with 
PEG-b-PAMA. 
 
Stress Tolerance of ASNase Formed PPC with PEG-b-PAMA 
PEGylation is one of the major strategies to stabilize pharmaceutical proteins in vivo due to the steric 
hindrance of PEG segments on the protein surface [7–12]. It is of interest to determine whether noncovalent 
interaction between ASNase and PEG-b-PAMA stabilizes the proteins to the same extent as in covalently 
conjugated PEGylated proteins toward various stresses, including proteolytic degradation and agitation. 
Therefore, commercially available PEG-ASNase was prepared as a model PEGylated protein. 
Figure 2.2.3A shows the enzyme activities of ASNase in the absence or presence of polymers 
preincubated with trypsin, which hydrolyzes peptide bonds at the carboxyl end of basic amino acids in the 
proteins. The residual activity of native ASNase was 15%, indicating that ASNase was inactivated by trypsin 
proteolysis. Similarly, ASNase in the presence of PAMA and PEG was inactivated by trypsin proteolysis. In 
contrast, the addition of PEG-b-PAMA showed a protective effect against trypsin proteolysis. The residual 
activity of ASNase/PEG-b-PAMA was 81%, which was higher than that of PEG-ASNase (47%). 
The proteolytic digestion of ASNase by trypsin was further evaluated by SDS-PAGE (Figure 
2.2.3B). Without trypsin treatment, only a band of monomeric size (35 kDa) was observed under all 
conditions. After trypsin digestion, the band of 35 kDa disappeared in the samples of ASNase alone, ASNase 
with PAMA, and ASNase with PEG. In contrast, the band of 35 kDa remained in the presence of 
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PEG-b-PAMA after trypsin treatment, corresponding with the residual activity (Figure. 2.2.3A). These 
results indicated that the PPC with PEG-b-PAMA had a protective effect against proteolysis by trypsin. 
 
 
 
The protective effects of PEGylated polyelectrolyte against shaking were then evaluated. A 
solution of native ASNase shaken at 500 rpm for 6 h showed visible suspension and the enzyme activity 
 
 
Figure 2.2.3. Proteolytic digestion of ASNase with polymer. (A) Residual activity of ASNase with polymers and 
PEG–ASNase after trypsin treatment. (B) SDS-PAGE of ASNase/polymer preincubated with or without trypsin 
treatment. Lane 1, native ASNase; lane 2, ASNase/PEG-b-PAMA; lane 3, ASNase/PAMA; lane 4, ASNase/PEG; M, 
standard ladder marker. 
 
33 
disappeared completely (Figure 2.2.4). DLS measurements indicated that Dh of native ASNase after shaking 
was >1000 nm (Table 2.2.1), suggesting that the native ASNase was inactivated due to aggregation induced 
by shaking. In contrast, the residual activity of ASNase with polymers remained above 75%, and that of 
PEG-ASNase remained at 47%. It is interesting to note that Dh of ASNase/PEG-b-PAMA after shaking 
remained constant, whereas those of other samples were above 1000 nm (Table 2.2.1). These results 
indicated that the PEGylated polyelectrolytes inhibited shaking-induced protein aggregation. 
 
 
Finally, the effects of PEGylated polyelectrolyte against heat-induced inactivation of ASNase were 
confirmed. Heating temperature was chosen 60oC because of the ASNase did not inactivated below 40oC 
(data not shown). The residual activities of native ASNase and PEG-ASNase were 55% and 38%, 
respectively (Figure 2.2.5). With the addition of nonionic PEG, there was a slight change in the residual 
activity to 60%. In contrast, the addition of cationic polyelectrolytes, PEG-b-PAMA and PAMA, the enzyme 
activities decreased about 10%. The ASNase and polyelectrolyte solutions after heating showed visible 
aggregates with Dh values >330 nm (Table 2.2.1). These results suggested that polyelectrolytes accelerated 
the heat-induced inactivation of ASNase. 
 
 
Figure 2.2.4. Residual activities of ASNase with polymers and PEG-ASNase after the shaking at 500 rpm for 6 
h.aaaaaa 
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Table 2.2.1. Hydrodynamic Diameters (Dh) of ASNase in the Absence or Presence of Polymers. 
 
  
Dh (nm)a 
 
 
No Stress Shaking Heating 
No Addition 10.8 ± 0.06 (0.20) > 1000 (0.92) 10.1 ± 0.13 (0.29) 
PEG-b-PAMA 26.2 ± 0.28 (0.46) 28.9 ± 0.38 (0.67) 330 ± 2.61 (0.18) 
PAMA > 1000 (1.00) > 1000 (1.00) > 1000 (0.88) 
PEG 11.3 ± 0.02 (0.22) > 1000 (0.84) 13.3 ± 0.40 (0.47) 
PEG-ASNase 24.5 ± 0.18 (0.25) > 1000 (1.00) 28.0 ± 3.01 (0.59) 
Parentheses show polydispersity index (PDI). 
aZ-average size. 
 
 
 
Figure 2.2.5. Residual activity of ASNase with polymers and PEG-ASNase after heat treatment at 60◦C for 2 h. 
aaaaaa 
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2.2.4. Discussion 
This study showed stabilization of therapeutic proteins using PEGylated polyelectrolytes, as 
summarized below. PEGylated cationic PEG-b-PAMA and anionic ASNase formed soluble complexes 
without conformational changes, whereas non-PEGylated PAMA formed aggregative complexes with 
conformational changes (Figures 2.2.2A,B), corresponding to the results reported previously [25]. This is 
because the electrostatic interactions between proteins and polyelectrolytes are driving forces that stabilize 
PPC, which was also supported by the control data in which noncharged PEG alone did not affect the size of 
ASNase (Table 2.2.1). In is interesting to note that the Dh of ASNase with PEG-b-PAMA was identical to 
that of PEG-ASNase (Table 2.2.1), suggesting that the conformation of the PPC with PEG-b-PAMA may be 
similar to that of PEGylated proteins. 
Several authors, including our group, reported previously that cationic polyelectrolytes can bind to 
anionic enzymes, resulting in inhibition of enzyme activities [23,25,30,31]. However, the results of the 
present study showed that the enzyme activity of ASNase did not change despite PPC formation (Figure 
2.2.2C). This unexpected difference in inhibition of polyelectrolytes may be due to several factors, such as 
the types of compounds, pH of the solution, and the method used for enzyme assay. Although it is difficult to 
determine whether polyelectrolytes inhibit the enzyme activity, PPC is more favorable for enzyme activity of 
ASNase than PEG-ASNase because the covalent PEGylation produces a decrease in activity of proteins 
[7–12]. Under the present experimental condition, the enzyme activities of native ASNase and PEG-ASNase 
were about 35 and 10 U/mL, respectively. 
PEG-conjugated proteins are protected from proteolytic digestion by proteases in vitro and in vivo. 
In fact, the residual activity of PEG-ASNase toward trypsin was higher than that of native ASNase (Figure 
2.2.3). In this study, PEG-b-PAMA protected ASNase from proteolytic digestion to a comparable extent to 
PEG-ASNase, whereas the PAMA and PEG did not (Figure 2.2.3). These results indicated that binding of 
PEG-b-PAMA to the surface of ASNase provided a shield. It was suggested that the protective mechanism of 
PPC with PEG-b-PAMA is similar to that of PEGylated proteins, that is, steric hindrance of PEG on 
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ASNase/PEG-b-PAMA complex inhibits access to protease. 
Shaking is one of the major causes of protein aggregation [3,4]. Aggregation by shaking is 
primarily attributable to the con- tact of proteins and air-water interfaces [4]. Our results indicated that native 
ASNase also formed visible aggregates on shaking stress (Table 2.2.1), resulting in inactivation of the 
enzyme (Figure 2.2.4). In contrast, the solutions of ASNase with polymer and PEG-ASNase were clear and 
retained enzyme activity. It is emphasized that the Dh of ASNase/PEG-b-PAMA after shaking remained 
constant, even though DLS measurement is sensitive to small amounts of aggregates. It is possible that the 
steric hindrance of PEG on the ASNase/PEG-b-PAMA complex conferred protection from the contact of 
air-water interfaces for the protein. 
The data for heat treatment on ASNase are complex, and it is difficult to understand the mechanism 
compared to other types of stress. Briefly, PEG-b-PAMA and PAMA accelerated irreversible inactivation of 
ASNase against heat treatment, whereas the others did not (Figure 2.2.5). This result was inconsistent with a 
previous report in which PEGylated polyelectrolyte stabilized hen egg white lysozyme against heat-induced 
inactivation [22]. It was suggested that the inconsistency resulted from monomeric or oligomeric forms of 
the proteins as follows. The tetrameric ASNase loses enzyme activity due to dissociation of subunits during 
heat treatment at 60oC, and then the enzyme activity is restored by decreasing temperature due to the 
reassociation of subunits [13,32] Furthermore, the denaturation temperature of ASNase is 62oC, which was 
independent even in the presence of polymers. Accordingly, the polyelectrolytes are thought to inhibit the 
reassociation of ASNase through electrostatic interaction, resulting in irreversible inactivation of ASNase. 
In summary, I showed that PEGylated polyelectrolytes stabilize the therapeutic protein, ASNase. 
PEG-b-PAMA successfully protected ASNase against trypsin digestion and shaking-induced aggregation 
due to PPC formation. The stabilizing effects of PPC with PEG-b-PAMA were similar to those of covalent 
PEGylated ASNase, suggesting that noncovalent PEGylation occurred with PEGylated polyelectrolytes. 
Other therapeutic proteins with multidomain structures would be stabilized by PEGylated polyelectrolytes. I 
believe that complex formation between PEGylated polyelectrolytes and proteins will expand the 
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applications of therapeutic proteins, such as formulation and drug delivery systems. 
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Chapter 3. Enzyme Hyperactivation 
 
3.1. Enzyme Hyperactivation System Based on a 
Complementary Charged Pair of Polyelectrolytes and 
Substrates 
 
3.1.1. Introduction 
The control of enzyme activity through noncovalent interaction has attracted widespread attention not only in 
biological studies, but also in innovative applications such as biosensors [1−3]. These artificial modulators 
are classified as inhibitors or activators. Several artificial inhibitors have been designed: for example, 
polymeric substrate analogs [4], dendrimers [5], molecular clips and tweezers [6], gold nanoparticles [7−10], 
and graphene oxides [11]. The binding of inhibitors to enzyme surfaces typically results in a decrease in 
enzyme activity. Our group have recently demonstrated that charged polyelectrolytes function as reversible 
inhibitors of various enzymes via a so called complementary polymer pair system (CPPS) [12−15]. Briefly, 
the formation of noncovalent complexes between enzymes and polyelectrolytes results in the complete 
prevention of enzyme activity; the subsequent addition of another charged polyelectrolyte can restore the 
enzyme activity by removing the binding polyelectrolytes from the enzyme. By contrast, artificial activators, 
such as polymer micelles [16−22], thermoresponsive microgels [23], gold nanoparticles [24,25], and 
graphene oxides [26], have been reported to increase enzyme activity through noncovalent interactions. 
However, strategies for the development of artificial modulators have typically focused on the binding of 
artificial modulators to enzyme surfaces. 
Here, I developed a unique hyperactivation system for enzymes that focuses on the electrostatic 
nature of both the polyelectrolytes and substrates. In this system, enzyme activation occurs immediately 
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when a polyelectrolyte is added to an enzyme solution containing a substrate whose electric charge is 
opposite that of the polyelectrolyte. In other words, a complementary charged pair is designed between the 
substrate and polyelectrolyte in addition to between the polyelectrolyte and enzyme. The enzyme activity of 
α-chymotrypsin (ChT) for a cationic substrate increased 7-fold in the presence of anionic poly(acrylic acid) 
(PAAc) and for an anionic substrate increased 18-fold in the presence of cationic poly(allylamine) (PAA) at 
pH 7.0. Analysis of salt and pH effects, enzyme kinetics, dynamic light scattering (DLS), and circular 
dichroism (CD) suggested that the hyperactivation is due to modulation of the charge distribution of the 
enzyme. 
 
 
3.1.2. Materials and Methods 
Materials 
α-Chymotrypsin (ChT) from bovine pancreas, N-succinyl-L-phenylalanine-p-nitroanilide (SPNA), and 3-(N- 
morpholino)propanesulfonic acid (MOPS) were from Sigma Chemical Co. (St. Louis, MO). Poly(acrylic 
acid) (PAAc) with an average molecular weight of 5.0 kDa and dimethyl sulfoxide (DMSO) were from 
Wako Pure Chemical Ind., Ltd. (Osaka, Japan). Poly(allylamine) (PAA) with an average molecular weight of 
5.0 kDa was from Nitto Boseki Co., Ltd. (Fukushima, Japan). Sodium chloride (NaCl) was from Nacalai 
Tesque, Inc. (Kyoto, Japan). N-Acetyl-L-phenylalanine-p-nitroanilide (APNA) was from Watanabe Chemical 
Ind., Ltd. (Hiroshima, Japan). N-Glycyl-L-phenylalanine-p-nitroanilide (GPNA) was from Bachem AG 
(Bubendorf, Switzerland). Ethanol was from Kanto Chemical Co., Inc. (Tokyo, Japan). All chemicals used 
were high-quality analytical grade and used as received. 
 
Protein Concentration 
The protein concentration of ChT was determined from the absorbance at 280 nm using a V-630 
spectrophotometer (Japan Spectroscopic Co., Ltd., Tokyo, Japan) and an extinction coefficient of 50,585 M−1 
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cm−1 [27]. 
 
Enzyme Assay 
All substrates used in this study were insoluble in pure water, and hence 9.0 mM MOPS (pH 7.0) with 9.0% 
ethanol and 1.0% DMSO was used as the solvent for the enzyme assays. A 30 µL aliquot of substrate 
solution containing 0−30 mM substrate (GPNA, APNA, or SPNA), 90% ethanol, and 10% DMSO was 
mixed with 120 µL of polyelectrolyte (PAA or PAAc) in 10 mM MOPS (pH 7.0) and 150 µL of 10 µM ChT 
in 10 mM MOPS (pH 7.0). The initial reaction velocities v0 were determined from the slope of the initial 
increase in the absorbance intensity at 410 nm. The absorbance was converted into concentration using a 
molar extinction coefficient for p-nitroaniline of 8,800 M−1 cm−1. Normalized enzyme activity was defined as 
the ratio of v0 in the presence of polyelectrolyte to v0 with no polyelectrolyte. For the salt effect studies, all 
parameters were unchanged except for the concentration of NaCl. The activity of ChT in the presence of the 
polyelectrolytes was normalized to that without polyelectrolytes at the same salt concentration because the v0 
of ChT for substrates changed slightly with increasing NaCl concentration. For pH effect studies, all 
parameters were unchanged except for the addition of 6.66 mM HCl/NaOH. For kinetics studies with PAA, 
all parameters were unchanged except for the concentration of MOPS. At higher concentrations of SPNA, a 
pH shift due to protons from SPNA could not be neglected, so that a high concentration of MOPS buffer 
(100 mM) was used to avoid changing the pH. 
 
Dynamic Light Scattering 
Dynamic light scattering (DLS) experiments were performed using a Zetasizer Nano ZS light scattering 
photometer (Malvern Instruments, Worcestershire, UK) equipped with a 4 mW He−Ne ion laser (λ = 633 
nm). The sizes of the enzyme with polyelectrolytes were determined as follows. Solutions containing 5.0 µM 
ChT, 0−5.0 µM polyelectrolytes, and 10 mM MOPS buffer (pH 7.0) were placed in a 1-cm path length 
disposable cuvette, and DLS measurements were performed at 25 oC at a detection angle of 173o. The 
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viscosity of the solutions was approximated by the value of the 10 mM MOPS solution (η = 0.87 cP). All 
results are presented as the average values of three independent experiments. 
 
Circular Dichroism 
Circular dichroism (CD) experiments were performed in a 1-mm path length quartz cuvette using a J-720 
spectropolarimeter (Japan Spectroscopic Co., Ltd., Tokyo, Japan). Solutions containing 5.0 µM ChT, 0 - 5.0 
µM polyelectrolytes, and 10 mM MOPS buffer (pH 7.0) were prepared, and the spectra were measured at 25 
oC. The CD spectra of the samples were corrected by subtracting the corresponding spectra of the buffers in 
the absence of enzymes. 
 
 
3.1.3. Results 
Hyperactivation of ChT by Polyelectrolytes 
Figure 3.1.1a illustrates the molecular structures of the enzyme, polyelectrolytes, and substrates used in this 
study. α-Chymotrypsin (ChT) is classified as a serine protease that hydrolyzes peptide bonds at the carboxyl 
end of aromatic amino acids in a given substrate. The enzyme hyperactivation system was investigated using 
three types of substrates: N-glycyl-L-phenylalanine-p-nitroanilide (GPNA) as a cationic substrate, N-acetyl- 
L-phenylalanine-p-nitroanilide (APNA) as a neutral substrate, and N-succinyl-L-phenylalanine-p-nitroanilide 
(SPNA) as an anionic substrate. Note that the initial velocities (v0) of native ChT for cationic GNPA and 
anionic SPNA were similar, with values of 13.6 ± 0.2 (nM/sec) and 18.4 ± 0.2 (nM/sec), respectively, 
whereas the activity for neutral APNA was three times higher, with a value of 43.2 ± 0.8 (nM/sec). Two 
types of polyelectrolytes were used: cationic PAA and anionic PAAc. Figure 3.1.1b shows the system for the 
hyperactivation of ChT with polyelectrolytes and charged substrates. ChT activity for the cationic substrate 
GPNA was enhanced by the addition of the anionic polyelectrolyte PAAc; conversely, ChT activity for the 
anionic substrate SPNA was enhanced by the addition of the cationic polyelectrolyte PAA. 
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Figure 3.1.2a shows the normalized activity of ChT when 5.0 µM enzyme was mixed with various 
concentrations of PAAc. As expected, the ChT activity for GPNA markedly increased with increasing 
concentrations of PAAc; the ChT activity increased approximately 7.0-fold (96.6 nM/sec) in the presence of 
5.0 µM PAAc (1.0 equiv). It should be noted that PAAc alone did not catalyze the hydrolysis of GPNA. By 
contrast, for the neutral substrate APNA and anionic substrate SPNA, ChT activity decreased 0.28-fold (12.1 
nM/sec) and 0.05-fold (0.8 nM/sec), respectively, in the presence of PAAc. These results clearly indicate that 
activation of ChT by anionic PAAc occurred only for the cationic substrate. Similarly, enzyme activity was 
measured in the presence of cationic PAA and the three types of substrates (Figure 3.1.2b). The activity of 
ChT for the anionic substrate SPNA was significantly enhanced upon the addition of cationic PAA; the 
enzyme activity was activated approximately 18.0-fold (321.0 nM/sec) by 50.0 µM PAA (10.0 equiv), 
whereas hydrolysis of SPNA by PAA alone was not observed. In contrast to the effects of PAAc, ChT 
activities for neutral APNA and cationic GPNA increased slightly with increasing PAA concentration, up to 
2.4-fold (108.0 nM/sec) and 1.5-fold (15.4 nM/sec), respectively, i.e., the effects of PAA increased in the 
 
 
Figure 3.1.1. (a) Tertiary structure of ChT (PDB entry 4CHA) and the chemical structures of the polyelectrolytes 
and substrates. Color scheme for enzymes: anionic residues, red; cationic residues, blue; hydrophobic residues, gray; 
hydrophilic residues, green; catalytic regions, orange. (b) Schematic illustration of ChT hyperactivation by 
polyelectrolytes. 
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order GPNA < APNA ≪ SPNA. Thus, an oppositely charged polyelectrolyte and substrate pair was 
necessary for higher activation of ChT. 
 
 
 
Effect of pH and Ionic Strength 
Because enzyme activity is influenced by pH [28], it is unclear from Figure 3.1.2 whether polyelectrolytes 
shift the optimum pH of ChT, resulting in an apparent activation of ChT. The effect of pH on enzyme 
activity in the presence and absence of polyelectrolytes was compared. Figure 3.1.3a shows the initial 
velocity (v0) for the hydrolysis of cationic GPNA by ChT in the absence and presence of anionic PAAc as a 
function of pH. Although the pH profile of v0 of ChT in the presence of PAAc slightly shifted to lower pH 
regions, the v0 of ChT in the presence of PAAc was much higher than that of ChT alone. In the pH range 
from 5.5 to 8.5, the maximum v0 for GPNA was 42.5 nM/sec at pH 8.5 and 227.0 nM/sec at pH 7.9 in the 
absence and presence of PAAc, respectively. A slight difference in the optimum pH was observed in the 
presence of cationic PAA and anionic SPNA (Figure 3.1.3b). PAA increased the v0 of ChT in the presence of 
PAA without affecting the optimal pH of ChT. In the pH range from 5.5 to 8.5, the maximum v0 for SPNA 
was 23.8 nM/sec at pH 7.7 and 856.0 nM/sec at pH 7.6 in the absence and presence of PAA, respectively. 
 
Figure 3.1.2. Normalized activity of ChT for three types of substrates in the presence of PAAc (a) or PAA (b). 
Various concentrations of polyelectrolytes were added to solutions containing 5.0 µM ChT and 0.8 mM substrate. 
GPNA, filled circles; APNA, open circles; SPNA, filled squares. 
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These results demonstrate that a shift in the optimal pH was not a primary cause of the activation of ChT. 
 
 
 
Subsequently, the effects of ionic strength on the enzyme activity of ChT in the presence of 
polyelectrolytes were tested. Figure 3.1.4a shows the normalized activity of ChT when various 
concentrations of NaCl were added to a solution containing 5.0 µM enzyme and 5.0 µM PAAc. The ChT 
activity for cationic GPNA concomitantly decreased with increasing concentrations of NaCl; the ChT 
activity reached approximately 100% upon the addition of 300 mM NaCl. Likewise, the ChT activities for 
neutral APNA and anionic SPNA reverted to approximately 100% upon the addition of 300 mM NaCl. A 
similar tendency was observed for cationic PAA. The ChT activities for the three substrates in the presence 
of PAA also reached approximately 100% upon the addition of 300 mM NaCl (Figure 3.1.4b). These results 
indicate that the activation of ChT activity by polyelectrolytes is primarily attributable to electrostatic 
interactions. 
 
 
Figure 3.1.3. Initial velocity (v0) of ChT in the absence and presence of polyelectrolytes at various pH values. (a) 0.8 
mM GPNA was added to solutions containing 5.0 µM ChT and 0 µM (filled circles) or 5.0 µM (open circles) PAAc. 
(b) 0.8 mM SPNA was added to solutions containing 5.0 µM ChT and 0 µM (filled circles) or 50.0 µM (open 
circles) PAA. 
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Kinetic Analysis of ChT in the Presence of Polyelectrolytes 
To obtain additional insight into the mechanism of hyperactivation, enzyme kinetic analyses were performed 
using various concentrations of polyelectrolytes. Figure 3.1.5a shows the Lineweaver-Burk plot of 1/v0 
versus 1/[S] for the hydrolysis of cationic GPNA by ChT in the absence and presence of anionic PAAc. The 
kinetic parameters were calculated from a linear fit to the Lineweaver-Burk equation for each PAAc 
concentration (Table 3.1.1). The addition of PAAc to ChT significantly decreased the Michaelis constant 
(KM), whereas the catalytic constant (kcat) remained essentially unchanged. These results indicate that the 
addition of PAAc enhanced the affinity of ChT for GPNA rather than the turnover number. 
A similar kinetic analysis was performed using various concentrations of cationic PAA (Figure 
3.1.5b). The kinetic parameters were calculated from a linear fit to the Lineweaver-Burk equation for each 
PAA concentration (Table 3.1.1). The addition of PAA to ChT not only decreased KM, similar to PAAc, but 
also increased kcat. These results suggest different mechanisms of ChT activation by PAA and PAAc, as 
discussed below. 
 
 
Figure 3.1.4. Normalized activity of ChT for three types of substrate in the presence of polyelectrolytes at various 
NaCl concentrations. (a) Solutions containing 5.0 µM ChT, 5.0 µM PAAc, and 0.8 mM substrate were mixed with 
various concentrations of NaCl. (b) Solutions containing 5.0 µM ChT, 50.0 µM PAA, and 0.8 mM substrate were 
mixed with various concentrations of NaCl. GPNA, filled circles; APNA, open circles; SPNA, filled squares. 
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Size and Secondary Structure of ChT in the Presence of Polyelectrolytes 
Regulation of enzyme activity by the formation of an enzyme-polyelectrolyte complex (EPC) was previously 
reported [12−15]. Thus, it is possible that the activation of ChT by polyelectrolytes is accompanied by EPC 
 
Figure 3.1.5. Lineweaver-Burk plots for the hydrolysis of substrate by ChT in the absence and presence of 
polyelectrolytes. (a) Various concentrations of GPNA were added to solutions containing 5.0 µM ChT and 0 µM 
(filled circles), 1.0 µM (open circles), or 2.5 µM (filled squares) PAAc. (b) Various concentrations of SPNA were 
added to solutions containing 5.0 µM ChT and 0 µM (filled circles), 5.0 µM (open circles), or 10.0 µM (filled 
squares) PAA. The lines represent the best fit for the data using the Lineweaver-Burk equation. 
Table 3.1.1. Values for the Catalytic Constant (kcat) and the Michaelis Constant (KM) at Various Concentrations of 
Polyelectrolytes 
Substrate [Polyelectrolyte] kcat[a] KM[a] 
  (µM) (10-2 sec-1) (mM) 
GPNA PAAc 
  
 
0 3.98 ± 0.13 9.76 ± 0.35 
 
1.0 4.19 ± 1.04 3.08 ± 0.98 
 
2.5 4.17 ± 0.14 1.26 ± 0.07 
SPNA PAA 
  
 
0 2.70 ± 0.11 2.76 ± 0.15 
 
5.0 6.70 ± 1.08 1.41 ± 0.37 
  10.0 7.13 ± 0.94 0.87 ± 0.02 
[a] Mean values ± standard deviation. 
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formation. Figure 3.1.6 shows a representative result for the particle size distribution of ChT in the absence 
and presence of polyelectrolytes, as monitored by DLS. The hydrodynamic diameter (Dh) of ChT alone was 
5.1 nm, whereas the Dh of the mixture of ChT and PAAc was 10.0 nm, twice that of ChT alone. By contrast, 
the Dh of the mixture of ChT with PAA was 6.7 nm, similar to the size of ChT alone. It is noted that the Dh 
of PAAc and PAA alone was not detected by DLS. These results indicated that anionic PAAc but not 
cationic PAA formed EPCs with cationic ChT. 
Figure 3.1.7 shows the far-UV CD spectra of ChT in the presence of the polyelectrolytes. The 
far-UV CD spectrum of ChT in the presence of PAAc was identical to that in the absence of PAAc, 
indicating that the secondary structure of ChT did not significantly change, even upon complexation with 
PAAc. Similarly, the far-UV CD spectrum of ChT did not change, even in the presence of PAA. Thus, 
polyelectrolytes did not induce significant conformational changes in ChT. 
 
 
 
Figure 3.1.6. Hydrodynamic diameter (Dh) of ChT in the absence and presence of polyelectrolytes. 5.0 µM ChT was 
mixed with 5.0 µM PAAc (a) or 5.0 µM PAA (b). Native enzymes, solid line; PAAc, broken line; PAA, dotted line. 
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3.1.4. Discussion 
This study presents a novel enzyme hyperactivation system employing pairs of polyelectrolytes and 
substrates. Previous studies showed that anionic PAAc inhibits cationic enzymes such as ribonuclease A, 
lysozyme, and trypsin, whereas cationic PAA inhibits anionic enzymes such as cellulase, α-amylase, and 
β-galactosidase [13−15]. A significant finding of this study is that both PAAc and PAA can function not only 
as inhibitors but also as activators of enzymes when appropriate substrates are selected. For example, anionic 
PAAc activated ChT during the hydrolysis of cationic GPNA, whereas cationic PAA inhibited ChT during 
the hydrolysis of the same substrate (Figure 3.1.2). Thus, whether polyelectrolytes inhibit or activate 
reactions is determined by the charge of the substrate: i.e., ChT is activated when polyelectrolytes are 
complementary to the substrate. ChT activity for a cationic substrate was increased 7-fold by anionic PAAc, 
and ChT activity was increased 18-fold for an anionic substrate by cationic PAA at pH 7.0, an enhancement 
of activity greater than that of previously reported artificial activators such as quaternary ammonium salts 
[29,30], surfactant micelles [31−35], quaternary polyamines [36], polymer micelles [5,19,20], and gold 
nanoparticles [24,25]. 
Common mechanisms of hyperactivation by both polyelectrolytes are suggested below. Both 
 
Figure 3.1.7. Far-UV CD spectra of ChT in the absence and presence of polyelectrolytes. 5.0 µM ChT was mixed 
with 5.0 µM PAAc (a) or 5.0 µM PAA (b). Native enzymes, solid line; PAAc, broken line; PAA, dotted line. 
 
52 
polyelectrolytes clearly enhanced the absolute activity of ChT for complementary charged substrates, as the 
enhancement of ChT activity could not be explained by a shift in the optimal pH (Figure 3.1.3). A kinetic 
study revealed that polyelectrolytes decreased the Michaelis constant (KM) when functioning as activators 
(Table 3.1.1), indicating that the hyperactivation of ChT by polyelectrolytes was related to increased affinity 
of ChT for the substrate. Electrostatic interactions played a crucial role in the change in KM because the 
enhancement of enzyme activity by polyelectrolytes reverted to original activity levels upon the addition of 
NaCl (Figure 3.1.4), which shielded the electrostatic interactions. Thus, electrostatic interactions among the 
enzyme, polyelectrolytes, and substrates are responsible for the enhancement of the affinity of the enzyme 
for the substrate. 
Modulation of the charge distribution on an enzyme surface affects the diffusional association 
between an enzyme and its substrates. For example, the electrostatic steering of the substrate toward the 
active site of human superoxide dismutase was enhanced by the mutation of two charged residues in 
proximity to the active site, resulting in an increased rate constant for the enzyme reaction [37]. As another 
example, electrostatic shielding of the active site catalytic triad increased the activity of a serine protease 
from Achromobacter lyticus [28, 38, 39]. Similarly, the surfaces of ChT are likely surrounded by additional 
charges derived from the polyelectrolytes, thereby facilitating substrate uptake into the substrate binding site 
of the enzyme. 
The mechanism of activation by PAAc differs from that of PAA. Such an electrostatic binding 
mechanism is plausible for PAAc because anionic PAAc can bind to cationic ChT (Figure 3.1.6a). The 
binding of charged polymers to various enzymes was also reported to accelerate the catalytic hydrolysis of 
substrates [16−19,21,22]. By contrast, the activity of cationic ChT or anionic substrates was increased by 
cationic PAA (Figure 3.1.2b), although the formation of EPCs between ChT and PAA was not clearly 
established (Figure 3.1.6b). These results indicate that weak interactions between PAA and ChT might exist 
at pH 7.0 despite their similar cationic characteristics. Interestingly, the turnover number (kcat) of ChT for 
anionic substrates was cat increased by the addition of cationic PAA but was not affected when anionic 
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PAAc was combined with cationic substrates (Table 3.1.1), which may explain the difference in 
hyperactivation induced by PAA and PAAc (Figure 3.1.2, 3.1.3). It is possible that PAA not only increases 
the affinity of the enzyme for the substrate but also lowers the activation energy of the substrate or stabilizes 
the intermediate state in the catalytic reaction of ChT. 
 
 
3.1.5. Conclusion 
In summary, I have developed a hyperactivation system for ChT based on charge-complementarity between 
polyelectrolytes and substrates. In this system, the enzyme activity of ChT was enhanced by approximately 1 
order of magnitude simply by the addition of polyelectrolytes with charges opposite to those of the substrates. 
Because of their simplicity, hyperactivation systems could be designed for other enzymes by combining 
substrates and polyelectrolytes based on charge. As the hyperactivation system does not require laborious 
mutagenesis or chemical modification of enzymes, I believe this system could expand the potential uses of 
enzymes in biomedical and biotechnological applications. 
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3.2. Effects of Multivalency and Hydrophobicity of Polyamines 
on Enzyme Hyperactivation of α-Chymotrypsin 
 
3.2.1. Introduction 
Enzymes have attracted a great deal of interest in biomedical and bioengineering fields because of their 
catalytic activity under aqueous conditions. The utility of enzymes would increase dramatically if we are 
able to enhance their activity at will. This would require the development of methods to enable us to increase 
an enzyme activity above that of the native enzyme, i.e., enzyme hyperactivation (or superactivation) [1]. 
There have been many investigations regarding enzyme hyperactivation using surfactant micelles [1–3] or 
ionic liquids [4]. Other methods have also been examined, such as mutagenesis [5–7], chemical modification 
[8, 9], immobilization of nanomaterials [10–14], and polyion complex micelles [15–19]. However, enzyme 
hyperactivation remains challenging due to the lack of systematic rules. 
Recently, I reported that charged polyelectrolytes markedly enhanced the enzyme activity of 
α-chymotrypsin (ChT) [20]. Enzyme hyperactivation using polyelectrolytes is based on a simple rule, i.e., 
the coexistence of a charged substrate and oppositely charged polyelectrolytes is necessary to enhance the 
enzyme activity of ChT. For example, the enzyme activity of ChT for cationic substrate increased in the 
presence of anionic poly(acrylic acid) (PAAc), whereas that for an anionic substrate increased in the 
presence of cationic poly(allylamine) (PAA). In addition to polyelectrolytes, charged modulators, such as 
quaternary ammonium salts [21, 22], surfactant micelles [23–27], polymeric micelles [11, 12], and gold 
nanoparticles [10, 13], have been shown to enhance ChT activity toward oppositely charged substrates. 
These studies suggested that the charge combination between substrate and modulator plays an important 
role in enzyme hyperactivation. 
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Polyamines, such as putrescine (Put), spermidine (Spd), and spermine (Spm), are low molecular 
weight linear cationic compounds that are ubiquitous to all living organisms. The functions of polyamines 
are varied in vivo, including the regulation of cell proliferation and differentiation [28, 29]. In addition, 
polyamines have a favorable property with protein as a solution additive in vitro, such as stabilization of 
protein against thermal aggregation and inactivation [30, 31] and solubilization of membrane proteins [32] 
due to their polycationic structures. In this study, I demonstrated that amine compounds, including 
polyamines, enhanced the enzyme activity of ChT toward anionic substrates. The enzyme activity of ChT 
toward anionic substrate increased 1.6 - 6.9-fold in the presence of 50 mM amine compounds at pH 7.5. The 
effects of amine compounds for ChT activity were depending on both the number of amines and the 
hydrophobicity of amine compounds. Enzyme kinetics revealed that the turnover number (kcat) and specific 
constant (kcat/KM) of ChT for anionic substrate were increased by amine compounds, whereas the Michaelis 
constant (KM) was not significantly altered. In addition, molecular dynamics (MD) simulation revealed that 
the amine compounds interacted weakly with ChT. It was suggested that the weak interaction between amine 
compounds and ChT plays an important role in enzyme hyperactivation. 
 
 
3.2.2. Materials and Methods 
Materials 
Cadaverine dihydrochloride (Cad), α-chymotrypsin (ChT) from bovine pancreas, 
3-(N-morpholino)propanesulfonic acid (MOPS), putrescine dihydrochloride (Put), and 
N-succinyl-L-phenylalanine-p-nitroanilide (SPNA) were from Sigma Chemical Co. (St. Louis, MO). 
Dimethyl sulfoxide (DMSO), ethylenediamine (EDA), ethylamine (EA), 1,6-hexanediamine (HDA), 
hydrochloric acid (HCl), 1,8-octanediamine (ODA), 1,3-propanediamine (PDA), and propylamine (PA) were 
from Wako Pure Chemical Ind., Ltd. (Osaka, Japan). Diethylenetriamine (DETA), and triethylenetetramine 
(TETA) were from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Sodium chloride (NaCl) was from 
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Nacalai Tesque (Kyoto, Japan). Spermidine trihydrochloride (Spd) and spermine tetrahydrochloride (Spm) 
were from MP Biomedicals (Irvine, CA). Ethanol was from Kanto Chemical Co., Inc. (Tokyo, Japan). All 
chemicals used were of high-quality analytical grade and used as received. 
 
Protein Concentrations 
The protein concentration of ChT was determined from the absorbance at 280 nm using a spectrophotometer 
(ND-1000; NanoDrop Technologies, Inc., Wilmington, DE) with an extinction coefficient of 50585 M-1cm-1 
[33]. 
 
Enzyme Assay 
A 30-µL aliquot of substrate solution containing 0 - 20 mM SPNA, 90% ethanol, and 10% DMSO was 
mixed with 260 µL of additive in 50 mM MOPS (pH 7.5) and 10 µL of 150 µM ChT in 1.0 mM HCl. The 
initial reaction velocities (v0) were determined from the slope of the initial increase in the absorbance at 410 
nm using a spectrophotometer (V-630; Japan Spectroscopic Co., Ltd., Tokyo, Japan). The absorbance was 
converted into concentration using a molar extinction coefficient for p-nitroanilide of 8800 M-1 cm-1. 
Normalized enzyme activity was defined as the ratio of v0 in the presence of additive to v0 in the absence of 
additive. 
 
Molecular Dynamics Simulation for Additives Surrounding ChT 
The microscopic states of the amine compounds surrounding the ChT molecule were studied in a water box 
using molecular dynamics (MD) simulations. Three 20-ns simulations were performed for each system. The 
calculations were performed three times for the ChT/amine compound system with and without SPNA. The 
system contained one ChT molecule, 25 amine compound molecules, 0 (System 1) or 10 (System 2) SPNA 
molecules, 19 (monocationic additive), 44 (bicationic additive), 69 (triple cationic additive), 94 (tetracationic 
additive) chloride ions, and about 12500 water molecules. ChT, amine compound, and SPNA molecules 
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were located randomly in the water box. The concentrations of amine compounds and SPNA in MD 
simulations were approximately 2-fold (100 mM amine compounds) and 20-fold (40 mM SPNA) higher than 
those in experiments, respectively. The ChT molecules were described using the AMBER ff99SB [34] force 
field (GAFF). The water molecules were described using the TIP3P model [35]. The amine compounds and 
SPNA molecules were described using the general AMBER force field (GAFF)[36]. A restrained 
electrostatic potential (RESP) charge was used for the amine compounds and SPNA [37]. The simulations 
were conducted with the NPT ensemble (298 K, 1 bar) in a rhombic dodecahedron box with an initial length 
of 84 Å. The temperature was controlled using a Langevin thermostat with a viscosity of 0.5 ps-1. The 
pressure was controlled by a Parrinello-Rahman barostat [38] with a relaxation time of 2.0 ps. The 
electrostatics were treated using the particle mesh Ewald (PME) method [39] with a 10 Å cutoff distance. 
The van der Waals interactions were expressed using the twin-range cutoff method with cutoff distances of 
10 and 12 Å. The covalent bonds for the hydrogen atoms in ChT, amine compounds, and SPNA were 
constrained using the linear constraint solver (LINCS) [40]. The covalent bonds in the water were 
constrained using the SETTLE algorithm. The integration time step was 2 fs. The simulations were 
conducted using the GROMACS 4.5.5 simulator [41]. 
 
 
3.2.3. Results 
Activation of ChT for Anionic Substrates by Additives 
Previously, I reported that activation of α-chymotrypsin (ChT) for anionic substrate were achieved in the 
presence of cationic polyelectrolytes with high molecular weight (5.0 kDa) [20]. To confirm the versatility of 
the phenomenon, various types of monoamines, diamines, triamines, and tetramines were used (Figure 3.2.1). 
First, the activation of ChT activity was investigated using naturally occurring amine compounds, so-called 
polyamine, putrescine (Put), spermidine (Spd), and spermine (Spm). The enzyme activity of ChT was 
investigated in the presence of amine compounds at pH 7.5 toward the hydrolysis of anionic substrate of 
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SPNA. Figure 3.2.2 shows the enzyme activity of ChT when 5.0 µM enzymes was mixed with various 
concentration of polyamines. The ChT activity increased with increasing concentrations of polyamines; the 
addition of 50 mM Put, Spd, and Spm resulted in enhancement of ChT activities by 2.1-fold, 4.6-fold, and 
5.6-fold, respectively. Note that the polyamines alone did not catalyze hydrolysis of the substrate, SPNA. 
The effects of polyamines increased in the order Put < Spd < Spm, corresponding to the number of amine 
groups (Put, 2; Spd, 3; Spm, 4). These results indicated that the cationic natural polyamines could enhance 
the enzyme activity of ChT for anionic substrates as well as cationic polyelectrolytes. 
 
 
 
 
Figure 3.2.1. Chemical structures of amine compounds. ertiary structure of ChT (PDB entry 4CHA) and the 
chemical 
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Subsequently, similar experiments were performed using several types of amine compounds with 
different numbers of amine groups and alkyl chains, as shown in Figure 3.2.1. Figure 3.2.3A shows the 
systematic analysis of the enzyme activity of ChT in the presence of 50 mM amine compounds. The effects 
of diamines increased in the order EDA < PDA < Put < Cad < HDA < ODA, corresponding to the number of 
alkyl chains (EDA, 2; PDA, 3; Put, 4; Cad, 5; HAD, 6; ODA, 8); similar tendencies were observed with 
monoamines (EA < PA), triamines (DETA < Spd), and tetramines (TETA < Spm). To evaluate the relation 
between the activation effects of ChT and hydrophobic nature of amine compounds, the values of normalized 
activity were compared with n-octanol/water partition coefficients (logP) of amine compounds obtained 
using the program ALOPGs [42] (Figure 3.2.3B). It is clear that enhancement of ChT activity was dependent 
on not only the number of anime groups but also the hydrophobicity of additives. 
 
 
Figure 3.2.2. Normalized activities of ChT for anionic substrates in the presence of polyamines. Various 
concentrations of polyamine were added to solutions containing 5.0 µM ChT and 2.0 mM SPNA. Put, filled circles; 
Spd, open circles; Spm, filled squares. 
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Kinetic Analysis of ChT in the Presence of Additives 
To understand the molecular mechanism of enzyme activation by the amine additives, kinetic parameters 
were obtained and compared with the number of amine groups and the hydrophobicity of amine compounds. 
Figure 3.2.4 shows plots of the hydrophobicity parameter of logP versus parameters obtained from 
Michaelis-Menten kinetics in the presence of amine compounds, EDA, Put, HDA, ODA, Spd, and Spm. The 
values of the catalytic constant (kcat) and specific constant (kcat/KM) of ChT with amine compounds were 
higher than those of ChT alone. These profiles were dependent on the types of amine compounds, similar to 
the plot of logP versus normalized activity (Figure 3.2.3B). In contrast, the value of the Michaelis constant 
(KM) of ChT did not change significantly with amine compounds. These results indicated that the addition of 
amine compounds enhanced the turnover number of ChT for SPNA rather than the affinity. 
 
 
Figure 3.2.3. (A) Normalized activities of ChT upon addition of 50 mM amine compounds. (B) Correlation 
between the logP of amine compounds and normalized activity of ChT. Black, monoamines; red, diamines; 
green, triamines; blue, tetramines. 
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Figure 3.2.4. Correlation between the logP of polyamines and kinetic parameters. (A) kcat, (B) KM, (C) kcat/KM. 
Broken lines show the value of ChT without additive. Red, diamines; green, triamines; blue, tetramines. 
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Molecular Dynamic Simulation of Interaction between Amine Compounds and ChT 
To elucidate the behavior of amine compounds in enzyme activation, molecular dynamic (MD) simulations 
of the ChT-amine system were conducted (system 1). MD simulation of one ChT molecule with 25 amine 
molecules in water was performed in a rhombic dodecahedron box with an NPT ensemble (P = 1 bar). Note 
that the concentration of amine molecules in MD simulation was 2-fold (100 mM) higher than those under 
experimental conditions. This was because the high concentration of amine molecules increases the 
probability of binding rates at calculation times under 20 ns. Figure 3.2.5 shows representative snapshots of 
the simulation using ODA. The ODA molecules, which were initially located randomly, bound onto the 
surface of ChT after 20 ns, and the average number of ODA molecules was 4.7 (Table 3.2.1). A similar 
tendency was observed with the addition of other amine molecules from 3.7 to 6.7 molecules (Table 3.2.1). 
Furthermore, additional MD simulations of the ChT-amine-SPNA system (system 2) were also conducted to 
mimic the conditions in experimental studies. MD simulation of one ChT molecule, 25 amine molecules, and 
10 SPNA molecules in water was calculated in a rhombic dodecahedron box with an NPT ensemble (P = 1 
bar). Note that the concentration of SPNA in the MD simulation was 20-fold (40 mM) higher than that under 
experimental conditions. Similar to the results obtained in system 1, the binding of amine molecules on the 
ChT surface was observed. Interestingly, the average number of amine molecules in system 2 tended to be 
greater than that in system 1 (Table 3.2.1). Thus, these results suggested that amine molecules weakly 
interact with ChT at neutral pH despite their similar cationic characteristics, which may increase the catalytic 
activity of ChT. 
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3.2.4. Discussion 
Several authors reported that enzyme hyperactivation of ChT was induced by a complementary charged 
modulator and substrate pair, i.e., anionic modulator activated ChT during hydrolysis of cationic substrates, 
and vice versa [10–13, 20–26]. Based on these reports, this study first demonstrated that naturally occurring 
polyamines and their analogs enhanced the enzyme activity of ChT toward anionic substrates (Figures 3.2.2, 
3.2.3A). It is important that the enzyme hyperactivation of ChT can be occurred desirable modulators if they 
coexist oppositely charged substrates. This unique behavior suggests the importance of the complementary 
charged substrate and modulator pair, and provides novel guidelines for hyperactivation of other types of 
enzymes. 
 
 
Figure 3.2.5. Snapshot of ChT and ODA molecules calculated by MD simulation. Spheres and cartoon represent 
ODA and ChT, respectively. The catalytic triad (His57, Asp102, and Ser195) is shown as red sticks. 
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The enzyme hyperactivation of ChT by amine compounds was seen with high dosage of additives 
(several mM) (Figure 3.2.2), which were much higher than those of cationic polyeletctrolytes, such as 
several µM of poly(allylamine) [20]. This difference was attributed to the multivalency and hydrophobicity 
of modulators. Enzyme hyperactivation of ChT by amine compounds was dependent on both the number of 
amine units and hydrophobicity of amine compounds (Figure 3.2.3B). Compared to the low molecular 
weight amine compounds, cationic poly(allylamine) has many amine units and greater hydrophobicity (logP 
of allylamine is 1.28). Thus, both multivalency and hydrophobicity of modulators are important parameters 
Figure 3.2.5. The average number of amine molecules within 4 Å of residues of ChT surfaces from MD simulation 
data. 
  Number of amine molecules 
 
System 1 System 2 
Amines ChT/Amines ChT/Amines/SPNA 
EA 3.67 ± 0.72 5.67 ± 0.72 
PA 4.67 ± 0.72 5.33 ± 1.19 
EDA 5.00 ± 0.82 6.00 ± 0.82 
PDA 4.67 ± 0.54 6.00 ± 0.00 
Put 6.00 ± 0.82 6.33 ± 0.27 
Cad 6.67 ± 0.27 6.33 ± 0.72 
HDA 5.33 ± 0.27 5.33 ± 0.72 
ODA 4.67 ± 0.72 6.67 ± 1.09 
DETA 6.67 ± 0.72 8.00 ± 0.94 
Spd 6.33 ± 0.27 8.00 ± 1.41 
TETA 6.67 ± 0.54 8.00 ± 0.00 
Spm 6.67 ± 1.10 6.67 ± 0.98 
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for enzyme hyperactivation of ChT. The generality of the simple correlation suggests the applicability to the 
other enzymes, as well as serine protease, with enhancement of activity by design of the substrate-additive 
pair. 
The interactions of amine compounds with proteins affect the structure and function of the proteins. 
For example, Hoyer et al. reported that amine compounds induced fibril aggregation of α-synuclein due to 
the formation of α-synuclein/amine compound complexes [43, 44]. Our results suggested the weak binding 
of amine compound onto the surface of ChT in MD simulation (Figure 3.2.5, Table 3.2.1). Thus, it was 
suggested that the weak intermolecular interaction between amine compounds and ChT contributed to the 
hyperactivation of ChT. Interestingly, a kinetic study indicated that amine compounds increased the catalytic 
constant (kcat) and specific constant (kcat/KM) depending on multivalency and hydrophobicity of amine 
compounds (Figure 3.2.4). It is possible that amine compounds also stabilize the intermediate state in the 
catalytic reaction of ChT or decrease the activation energy of the substrate. 
 
 
3.2.5. Conclusion 
In summary, I demonstrated enzyme hyperactivation of ChT using polyamines and their analogs. The 
activation effects of amine compounds were dependent on the multivalency and hydrophobicity of the 
structures. This study provided extended design parameters for artificial modulators of enzyme 
hyperactivation. Furthermore, the present results also demonstrated the novel function of polyamines as 
enzyme activators in vitro, implying that the unclear function of polyamines in living cell system existed. 
Although the detailed mechanisms underlying the enzyme hyperactivation induced by the charged 
substrate/modulator pairs remain unclear, it is noteworthy that enzyme activity was affected by small 
compounds as well as polyelectrolytes. This paper suggests the possibility that enzyme activities in crude 
and complex conditions, typical of those in vivo, are quite different from those seen under simple in vitro 
experimental conditions. Finally, I emphasize that the enzyme hyperactivation by several modulators, 
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including polyamines, could expand the potential uses of enzymes in biomedical and biotechnological 
applications. 
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Chapter 4. Precipitation-redissolution Method 
 
4.1. Protein-Poly(amino acid) Complex Precipitation for 
High-concentration Protein Formulation 
 
4.1.1. Introduction 
Therapeutic proteins have increased dramatically in both number and frequency of use [1]. At present, more 
than 200 different biopharmaceutical agents are approved for clinical application by the US Food and Drug 
Administration, and many more are currently in the development [2]. In some cases, effective therapy using 
proteins requires preparation of a high-concentration protein solution. For example, the desired concentration 
of proteins is above 100 mg/mL with a volume limitation of 1.5 mL for subcutaneous injection of therapeutic 
antibodies [3,4]. The simplest method for producing high-concentration protein formulations is dissolution of 
lyophilized formulation in a low volume of physiological saline. However, the lyophilized formulation 
requires a long dissolution time, which places a limitation on its practical usage [5]. 
Methods for concentration of protein solutions play important roles in the preparation of 
high-concentration protein formulations. The industrial development of high-concentration protein 
formulations has been achieved by various conventional separation techniques such as ultrafiltration, drying, 
chromatography, and dialysis [3] Recently, novel laboratory scale concentration methods such as gelation,6 
crystallization [7], nanoparticle formation [8], liquid-liquid phase separation [9], and combination with 
suspension and spray drying [10,11] have been reported for therapeutic proteins. Precipitation has great 
potential as an alternative concentration method for both ease and scalability. If the protein precipitate can be 
fully redissolved in some way, such precipitated protein represents a concentrated state of protein. Matheus 
et al. [12] reported the feasibility of high-concentration antibody formulation by the 
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precipitation-redissolution method using typical precipitants such as sodium citrate, ammonium sulfate, and 
poly(ethylene glycol) (PEG) 4000. However, high concentrations of the precipitants are required and 
therefore the precipitation-redissolution method remains limited to in vitro experiments. 
Polyelectrolytes have also been used as precipitants in biological and biotechnological methods, 
including protein purification [13–18]. The polyelectrolyte interacts strongly with complementary charged 
protein through multiple electrostatic interactions, resulting in the formation of various types of 
protein-polyelectrolyte complexes (PPC) [19]. PPCs are prone to form precipitates depending on several 
factors such as stoichiometric ratio, pH, temperature, and ionic strength. Our group have recently shown that 
the formation of PPCs could be achieved to regulate enzyme activity and to stabilize protein structure 
[20–23]. To our knowledge, however, few studies concerning PPCs precipitation of therapeutic proteins have 
been reported because of the pharmaceutical demerit of protein precipitation such as irreversible aggregation 
or cytotoxicity. 
In this study, a precipitation-redissolution method using poly(amino acid) as a precipitant was 
developed for several types of pharmaceutical proteins, including therapeutic enzymes, antibodies, and 
hormones. All proteins were fully precipitated by poly-L-lysine or poly-L-glutamic acid at low ionic strength, 
and the precipitates were then dissolved at physiological ionic strength of 150 mM sodium chloride (NaCl). 
The redissolved proteins retained the original activity and native secondary structure. The feasibility of the 
precipitation-redissolution method using poly(amino acid) for concentration of protein is discussed. 
 
 
4.1.2. Materials and Methods 
Materials 
Proteins: L-Asparaginase was purchased from Kyowa Hakko Kirin Company Ltd. (Tokyo, Japan) and used 
without further purification. Adalimumab (Eisai Company, Ltd., Tokyo, Japan), infliximab 
(Mitsubishi-Tanabe Pharmaceutical Company, Ltd., Osaka, Japan), omalizumab (Novartis Pharma KK, 
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Tokyo, Japan), and rituximab (Zenyaku Kogyo Company, Ltd., Tokyo, Japan) were obtained via reagent 
distributors and purified on a Protein A column to remove the cosolutes. Etanercept (Takeda Phar- 
maceutical Company, Ltd., Osaka, Japan) and panitumumab (Takeda Pharmaceutical Company) were 
obtained via reagent distributors and purified on a dextran gel column to remove the salts. Human IgG was 
from Equitech-Bio, Inc. (Kernville, Texas) and dialyzed to remove the cosolutes. Carperitide was from 
Daiichi-Sankyo Company, Ltd. (Tokyo, Japan) and purified on a silica gel column to remove the cosolutes. 
Thyroglobulin was separated from molecular weight standards (151-1901; Bio-Rad Laboratories, Hercules, 
California) by size-exclusion chromatography. 
Others: Ammonium sulfate, L-asparagine (L-Asn), citrate, Nessler’s reagent, sodium chloride 
(NaCl), and trichloroacetic acid (TCA) were from Kanto Chemical Company, Inc. (Tokyo, Japan). 
Polysorbate 20 was from Wako Pure Chemical Ind., Ltd. (Osaka, Japan). 3-(N-morpholino)Propanesulfonic 
acid (MOPS) was from Nacalai Tesque, Inc. (Kyoto, Japan). Tris(hydroxymethyl)aminomethane (Tris) was 
from Bio-Rad Laboratories. Biotinylated anti-human IgG, poly-L-glutamic acid sodium salt with average 
molecular weight of 1.5-5.5 kDa (polyE1) and 3.0-15 kDa (polyE2), and poly-L-lysine hydrobromide with 
average molecular weight of 4.0-15 kDa (polyK1) and above 30 kDa (polyK2) were from Sigma Chemical 
Company (St. Louis, Missouri). Human IgE was from Abcam (Cambridge, Massachusetts). Human tumor 
necrosis factor α (TNF-α) was from Gibco Life Technologies Ltd. (Grand Island, New York). 
Streptavidin-labeled horseradish peroxidase was from Thermo Fisher Scientific (Waltham, Massachusetts). 
3,3’,5,5’-Tetramethylbenzidine (TMB) was from KPL (Gennep, the Netherlands). These chemicals were of 
high- quality analytical grade, and were used as received. 
 
Precipitation-Redissolution Method 
Aliquots of 200 µL of precipitant solution containing 0-1.0 mg/mL poly(amino acid) (polyK1, polyK2, 
polyE1, or polyE2) and 10 mM buffer [citrate (pH 5.0-5.4), MOPS (pH 6.5-7.0), or Tris (pH 8.0-8.7)] were 
mixed with 200 µL of proteins in the same buffer, and then the samples were centrifuged at 15,000g for 20 
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min at 25oC. Subsequently, 360 µL of supernatant was replaced with another buffer containing 10 mM buffer 
and 167 mM NaCl. The concentrations of proteins were determined form the absorbance at 280 nm using a 
spectrom- eter (SpectraMax Plus384; Molecular Devices Company, Ltd., Sunnyvale, California). 
 
Enzyme Assay 
The enzyme activity of L-asparaginase was measured as follows. An aliquot of 50 µL of L-asparaginase 
solution was incubated with 950 µL of the substrate solution containing 22 mM L-Asn at 37oC for 15 min. 
The reaction was stopped by the addition of 250 µL of 1.5 M TCA to the assay mixture. Subsequently, the 
sample was mixed with Nessler’s reagent to measure the amount of ammonia released after L-Asn hydrolysis. 
The absorbance was monitored spectrophotometrically at 450 nm. The concentration of ammonia produced 
by the enzyme reaction was determined from a reference curve using ammonium sulfate as the standard. One 
unit of enzyme activity was defined as the amount of enzyme required to produce 1.0 µmol ammonia per 
minute at 37oC. 
 
Immunoassay 
The immnunoreactivities of four types of antibodies were measured as follows. The wells of polystyrene 
96-well ELISA microplates (Sumitomo Bakelite Company, Ltd., Tokyo, Japan) were coated with antigens 
(human TNF-α for adalimumab, etanercept, and infliximab; human IgE for omalizumab), and the plates 
were incubated at 4oC overnight. The wells were washed five times by the addition of washing buffer 
containing 24.8 mM Tris, 136.9 mM NaCl, 2.7 mM potassium chloride, and 0.1% polysorbate 20 (pH 7.4). 
The wells were then blocked with Blocking One (Nacalai Tesque) at room temperature for 1 h. After 
washing of the wells, 100 µL of the antibody solutions with different concentrations was added to the wells 
and incubated at room temperature for 1 h. After washing of the wells, 100 µL of biotinylated anti-human 
IgG was added to each well and incubated at room temperature for 1 h. After washing of the wells, 100 µL 
of streptavidin-labeled horseradish peroxidase was added to each well and incubated at room temperature for 
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30 min. After washing of the well, 100 µL of TMB was added to each well and incubated in the dark at room 
temperature for more than 15 min. Finally, 100 µL of 0.1% HCl was added, and the absorbance at 450 nm 
was determined using a microplate reader (SpectraMax Plus384; Molecular Devices). 
 
Circular Dichroism 
Circular dichroism (CD) experiments were performed in a 1-mm path-length quartz cuvette using a 
spectropolarimeter (J- 720; Japan Spectroscopic Company, Ltd., Tokyo, Japan). The spectra of redissolved 
proteins were measured at 25oC. The CD spectra of the samples were corrected by subtracting the 
corresponding spectra of the buffers in the absence of proteins. 
 
 
4.1.3. Results 
Precipitation-redissolution methods for proteins were performed using four types of poly(amino acids), that 
is, cationic poly-L-lysine with average molecular weight of 4.0-15 kDa (polyK1) and above 30 kDa (polyK2) 
or anionic poly-L-glutamic acid with average molecular weight of 1.5-5.5 kDa (polyE1) and 3.0-15 kDa 
(polyE2). The examination procedures are shown in Figure 4.1.1. First, poly(amino acid) was added to the 
protein solution in buffer without NaCl (Stage 1) and immediately suspended (Stage 2). Subsequently, the 
suspensions were precipitated by centrifugation (Stage 3), followed by removal of the supernatant (Stage 4). 
Finally, other buffers with NaCl were added to the precipitants, which were fully dissolved (Stage 5). The 
final concentration of NaCl (150 mM) corresponded to physiological ionic strength. 
First, the precipitation-redissolution method was investigated for two proteins, L-asparaginase (pI = 
4.7) that is used for acute lymphoblastic leukemia and adalimumab (pI = 8.7) that is used for rheumatoid 
arthritis. Anionic L-asparaginase with cationic polyK1 in 10 mM MOPS (pH 7.0) and cationic adalimumab 
with anionic polyE2 in 10 mM MOPS (pH 6.5) were chosen as models. The solutions of 0.5 mg/mL 
L-asparaginase with various concentrations of polyK1 were mixed. The protein solution with 0.025 mg/mL 
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(0.05 eq.) polyK1 showed a visible suspension, whereas that with above 0.3 mg/mL (>0.6 eq.) polyK1 
became clear. After centrifugation, the supernatant (90% of the total volume) was removed, and the same 
volume of 10 mM MOPS (pH 7.0) with final concentration of 150 mM NaCl was added to the precipitate, 
which was completely dissolved. Figure 4.1.2a shows the concentration of L-asparaginase at Stage 5 (CStage5). 
The CStage5 of L-asparaginase without polyK1 was 0.05 mg/mL, whereas that in the presence of 0.025 mg/mL 
(0.05 eq.) polyK1 was 0.5 mg/mL, indicating that almost all of the L-asparaginase was precipitated. When a 
high concentration of polyK1 was added to the protein solution, CStage5 decreased by 0.07 mg/mL in the 
presence of 0.5 mg/mL (1.0 eq.) polyK1. The decrease in CStage5 corresponded to the decrease in suspension 
at Stage 2. A similar tendency was observed in cationic adalimumab with anionic polyE2 (Figure 4.1.2b). 
The CStage5 of adalimumab with 0.025 mg/mL (0.05 eq.) polyE2 increased to 0.51 mg/mL, whereas it 
decreased with further addition of polyE2. These results suggested that cationic polyK and anionic polyE 
significantly precipitated anionic and cationic proteins, respectively. 
 
 
 
 
Figure 4.1.1. Outline of precipitation-redissolution method for L-asparaginase. Stock solution containing 1.0 mg/mL 
L-asparaginase in 10 mM MOPS (pH 7.0) (Stage 1). Aliquots of 200 µL of poly(amino acid) were added to 200 µL 
of stock solution at low ionic strength (Stage 2). After centrifugation (Stage 3), 360 µL of supernatant was removed 
(Stage 4) and then added to 360 µL of buffer containing NaCl (Stage 5). 
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To confirm the generality of the precipitation-redissolution method, similar experiments were performed 
using eight pharmaceutical proteins, that is, panitumumab (pI = 6.9), etanercept (pI = 8.0), thyroglobulin (pI 
= 5.5), carperitide (pI = 10.5), infliximab (pI = 8.7), rituximab (pI = 8.7), omalizumab (pI = 7.6), and IgG (pI 
= 6.9). Table 4.1.1 lists the experimental conditions with precipitant poly(amino acid), pH, and 
stoichiometric ratio for each protein. Note that precipitation occurred only when poly(amino acid) had a 
charge complementary to that of the protein at experimental pH, that is, positively charged polyK 
precipitated negatively charged proteins, and vice versa. Thus, conditions were screened based on 
electrostatic pairing between protein and poly(amino acid) as a function of pH. As expected, anionic 
panitumumab and etanercept at pH 8.7 and thyroglobulin at pH 7.0 were precipitated with the addition of 
 
 
Figure 4.1.2. Concentrations at Stage 5 for two types of proteins by poly(amino acid). Various concentrations of 
polyK1 or polyE2 were added to solutions containing 0.5 mg/mL L-asparaginase (a) or adalimumab (b), 
respectively, at Stage 2. 
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cationic polyK; the highest yields of the anionic proteins were above 86%. Similarly, cationic carperitide at 
pH 7.0, infliximab and rituximab at pH 6.5, omalizumab at pH 5.5, and IgG at pH 5.0 were precipitated with 
the addition of anionic polyE; the highest yields of the cationic proteins were above 89%. Therefore, It was 
suggested that the precipitation-redissolution method was effective for various types of proteins. 
 
 
 
 
 
Table 4.1.2. Enzyme activities or immunoreactivities of redissolved proteins. 
Protein (pI) Precipitant Buffer (pH) [Precipitant] / [Protein] ActivityControl ActivityStage5 Relative Activity 
            (%) 
L-Asparaginase (4.7) polyK1 MOPS (7.0) 0.05 2065 (U/mg) a 1943 (U/mg) a 94 
Etanercept (8.0) polyK2 Tris (8.7) 0.08 179 (pM) b 171 (pM) b 105 
Adalimumab (8.7) polyE2 MOPS (6.5) 0.05 279 (pM) b 271 (pM) b 103 
Infliximab (8.7) polyE2 MOPS (6.5) 0.05 354 (pM) b 368 (pM) b 96 
Omalizumab (7.6) polyE2 Citrate (5.5) 0.05 70 (pM) b 71 (pM) b 99 
a One unit of enzyme activity is the amount of enzyme required to produce 1.0 µmol ammonia per 1 min at 37oC. 
b The 50 % effective concentration (EC50). 
Table 4.1.1. Experimental conditions with the highest yields of several types of protein. 
Protein (pI) Precipitant Buffer (pH) [Precipitant] / [Protein] CStage2 CStage5 Yield 
        
 
(mg/mL) 
 
(mg/mL) 
(%) 
Panitumumab (6.9) polyK1 Tris (8.7) 0.100 0.50 0.49 98 
Etanercept (8.0) polyK2 Tris (8.7) 0.080 1.00 0.86 86 
Thyroglobulin (5.5) polyK1 Tris (8.0) 0.050 0.25 0.22 88 
L-Asparaginase (4.7) polyK1 MOPS (7.0) 0.050 0.50 0.51 102 
Carperitide (10.5) polyE1 MOPS (7.0) 0.300 0.50 0.47 94 
Adalimumab (8.7) polyE2 MOPS (6.5) 0.050 0.50 0.51 100 
Infliximab (8.7) polyE2 MOPS (6.5) 0.050 1.00 1.03 103 
Rituximab (8.7) polyE2 MOPS (6.5) 0.075 1.00 1.00 100 
Omalizumab (7.6) polyE2 Citrate (5.5) 0.050 1.00 0.95 95 
IgG (7.3) polyE2 Citrate (5.0) 0.150 1.00 0.89 89 
 
 
83 
Subsequently, the protein activities at Stage 5 were measured to determine whether the redissolved 
proteins retained their original activities. The enzyme activity of L-asparaginase at Stage 5 was comparable 
to that without polyK1 (Table 4.1.2). Similarly, there was no significant change in antigen-binding activity; 
the 50% effective concentration values of the antibodies at Stage 5 were equivalent to those without 
poly(amino acid) (Figure 4.1.3, Table 4.1.2). These results indicated that the precipitation-redissolution 
process did not affect protein activities. 
 
 
 
 
 
 
Figure 4.1.3. Immunoreactivities of etanercept (a), adalimumab (b), infliximab (c), and omalizumab (d) at Stage 5. 
Proteins were mixed with poly(amino acid) (shown in Table 4.1.1). Native proteins, closed circles; redissolved 
proteins, open circles. 
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Figure 4.1.4 shows the far-UV CD spectra of proteins at Stage 5 to determine whether any 
conformational changes occurred in the proteins. The far-UV CD spectra of antibodies at Stage 5 were 
identical to those of native proteins, although slight changes were observed in the far-UV CD spectra of 
panitumumab and IgG at Stage 5. These results suggested that the secondary structures of redissolved 
antibodies were significantly maintained. In contrast, far-UV CD spectra of L-asparaginase and thyroglobulin 
at Stage 5 seemed to have subtle peak shifts, indicating that the effect of secondary structure by 
precipitation-redissolution method was dependent on the properties of the protein. 
 
 
 
Figure 4.1.4. Far-UV CD spectra of panitumumab (a), etanercept (b), thyroglobulin (c), L-asparaginase (d), 
adalimumab (e), infliximab (f), rituximab (g), omalizumab (h), and IgG (i) at Stage 5. Proteins were mixed with 
poly(amino acid) (shown in Table 4.1.1). Native proteins, solid lines; redissolved proteins, dotted lines. 
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4.1.4. Discussion 
This paper described a precipitation-redissolution method using poly(amino acid). All types of proteins 
examined, including a pharmaceutically important enzyme, antibody, and hormone, were fully precipitated 
by poly(amino acid) (Table 4.1.1). The precipitant was dissolved under physiological ionic strength at 150 
mM NaCl. The most important observation was that the activities of redissolved proteins after precipitation 
were comparable to those of the respective native proteins (Figure 4.1.3, Table 4.1.2). Previous studies 
showed that polyelectrolytes inhibited enzyme activities at low ionic strength [20–23], because of the 
formation of PPCs. Thus, the recoveries of protein activities by buffer exchange observed in the present 
study indicated that proteins were released from PPCs, and hence redissolved proteins retained their native 
states. Accordingly, the redissolved proteins are likely to be applicable for protein therapy. 
The precipitation-redissolution method using poly(amino acid) is summarized in Figure 4.1.5. 
Poly(amino acid) binds to oppositely charged protein surfaces through electrostatic interactions at low ionic 
strength, and thus precipitable PPCs are formed [24,25]. The salts at high ionic concentration shield the 
electrostatic interaction between proteins and poly(amino acid), resulting in disruption of PPC precipitation 
[24,25] The salt responsiveness of protein precipitate is not observed by commonly used precipitants, 
including salt, organic solvent, or uncharged polymer, because of the differences in the mechanism of protein 
precipitation [26–29]. It should be noted that PPC precipitants were occurred in the pH range of | pH - pI | ≈ 
2. A similar tendency was reported in the precipitation ratio of antibodies by polyelectrolytes as a function of 
pH [16], indicating that the PPCs were likely to precipitate under these conditions. 
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Another significant advantage of the precipitation-redissolution method using poly(amino acid) is 
the low dosage of poly(amino acid) required to precipitate a protein. For example, proteins at 1.0 mg/mL 
were fully precipitated by the addition of 0.05-0.3 mg/mL poly(amino acid) (Table 4.1.1), which is much 
lower than the dosages of conventional precipitants used such as 200 mg/mL ammonium sulfate and 90 
mg/mL PEG [12]. Low dosage of poly(amino acid) may be preferable for protein formulation from a 
pharmaceutical perspective, as high concentrations of additives result in several practical limitations for 
cytotoxicity. On the contrary, the yield of PPC precipitation decreased with further addition of poly(amino 
acid) (Figure 4.1.2). This behavior is similar to the previous studies [25,30] in that an excess of 
polyelectrolyte increased protein molecules per unit of polyelectrolyte, resulting in repulsion between PPCs 
and a decline in precipitable PPCs. From a mechanistic viewpoint, it is reasonable that low concentrations of 
poly(amino acid) are required for PPC precipitation.  
Interestingly, peak shifts of the far-UV CD spectra were observed for redissolved oligomer proteins 
such as L-asparaginase and thyroglobulin, whereas those of redissolved antibodies were almost identical to 
the native state, although there were slight changes for panitumumab and IgG (Figure 4.1.4). This difference 
may arise from the following properties. First, the residual interactions between poly(amino acid) and 
proteins may affect the secondary structure of redissolved proteins at physiological ionic strength [25]. 
Second, the tertiary structures of proteins may be due to the differences in structural stability of redissolved 
proteins; oligomeric protein contain assembly homo- or heterosubunits through non-covalent interactions, 
whereas antibodies are roughly Y-shaped with a disulfide bond between two heavy chains and two light 
 
Figure 4.1.5. Schematic illustration of the precipitation–redissolution method by poly(amino acid). 
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chains. Although it is difficult to further discuss the dominant factors of poly(amino acid) on secondary 
structure of protein, antibodies may be more suitable for the precipitation-redissolution method than other 
proteins. 
In summary, this paper presented a unique precipitation-redissolution method using poly(amino 
acid) for several types of therapeutic proteins. As dilute proteins can be fully precipitated at low ionic 
strength, it is possible to prepare high-concentration protein formulations by redissolution in a lower volume 
of salt-containing buffer. In addition, the precipitation-redissolution method does not require particular 
instruments and therefore process development and scale-up may be feasible. Therefore, this system could be 
expanded for the concentration of therapeutic proteins as well as for protein purification. 
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4.2. Feasibility of Antibody-Poly(glutamic acid) Complexes: 
Preparation of High-concentration Antibody Formulations and 
Their Pharmaceutical Properties 
 
4.2.1. Introduction 
Monoclonal antibodies have generated considerable interest as biopharmaceuticals over the past two decades 
because of their high target specificity and biocompatibility. At present, over 20 types of monoclonal 
antibody have been approved by the US Food and Drug Administration [1] and used for several types of 
disease, such as cancer and autoimmune diseases [2–5]. Despite the advances in antibody drug development, 
the routes of administration for these antibodies remain challenging. The major route of delivery for 
antibodies has been intravenous administration due to the high bioavailability [6]. In contrast, subcutaneous 
administration has been in great demand as an alternative route that allows at-home administration by 
patients and improves compliance rates [7–10]. However, the desirable concentration of antibodies for 
subcutaneous administration is usually above 100 mg/mL with a volume limitation of 1.5 mL [9, 10]. 
Several methods have been developed to obtain high-concentration protein solutions that would 
enable proteins to be used in formulations, for example with additives such as arginine or other amino acids 
[11, 12], ultrafiltration [13], gelation [14], crystallization [15], liquid–liquid phase separation [16], and spray 
drying [6, 17]. However, these methods are still time-consuming and costly. Methods for the suspension or 
precipitation of protein have also been reported for use in concentrated protein formulations [18, 19]. If the 
precipitates of protein can be fully resolubilized by the simple method, such precipitates can be used as 
concentrated protein solutions. Recently, our group have demonstrated the precipitation–redissolution 
method with poly(amino acid) as a precipitant [20]. Briefly, charged polyelectrolytes, including 
poly-L-lysine and poly-L-glutamic acid, interact strongly with complementary charged proteins through 
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multiple electrostatic interactions, resulting in the formation of a protein–polyelectrolyte complex (PPC) 
[20–26], which can often be precipitated depending on the experimental conditions, such as pH, ionic 
strength, and stoichiometric ratio [24, 27, 28]. PPC precipitates are then redissolved by the addition of buffer 
with high ionic strength such that the final concentration reaches 150 mM, which corresponds to 
physiological conditions [20, 28, 29]. This simple system has been applied successfully for several types of 
therapeutic protein, including enzymes, antibodies, and peptide hormones [20]. However, the utility of this 
precipitation–redissolution method for protein therapy is still unclear. 
In this study, the feasibility of the complex precipitation–redissolution method using poly(amino 
acid) was demonstrated for high-concentration antibody formulation. As described below, antibody 
formulations with concentrations over 100 mg/mL of adalimumab for autoimmune disease and omalizumab 
for allergic asthma could be prepared by addition of poly-L-glutamic acid (polyE). The formation of 
antibody−polyE complex and precipitation–redissolution processes did not significantly change the 
immunoactivity or secondary structure of the antibodies, and did not result in undesirable aggregation. 
Comparison of time required, yield, and aggregate ratio indicated that the precipitation–redissolution method 
was more effective for application than the conventional concentration methods, including 
lyophilization–redissolution, evaporation–redissolution, and ultrafiltration. The precipitation–redissolution 
method was successfully performed from a scale of 400 µL to 1.0 L, indicating that this method could be 
scaled up to 2500-fold. Finally, the general toxicity and pharmacokinetic profiles of the antibody–polyE 
complex formulation were similar to those of conventional antibody formulations. These results suggested 
that this simple method represents a new strategy for preparing high-concentration antibody formulations, 
and it is expected that this method and complex formulations would be applicable for medicinal use. 
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4.2.2. Materials and Methods 
Materials 
Adalimumab was obtained from transfected Chinese hamster ovary (CHO) cell cultures and purified on a 
protein-A column. Omalizumab was purchased from Novartis Pharma KK (Tokyo, Japan) and purified on a 
protein-A column to remove the additives. Citrate, sodium chloride (NaCl), sodium phosphate, and 
potassium chloride (KCl) were from Kanto Chemical Co., Inc. (Tokyo, Japan). Polysorbate 20 was from 
Wako Pure Chemical. Ind., Ltd. (Osaka, Japan). 3-(N-morpholino)Propanesulfonic acid (MOPS) and 
Blocking One were from Nacalai Tesque, Inc. (Kyoto, Japan). Tris(hydroxymethyl)aminomethane (Tris) was 
from Bio-Rad Laboratories (Hercules, CA). Biotinylated anti-human IgG monoclonal antibody, rat IgG, and 
poly-L-glutamic acid sodium salt with average molecular weights of 3000 – 15000 Da (polyE1) and 50000 – 
100000 Da (polyE2) were from Sigma Chemical Co. (St. Louis, MO). Human IgE was from Abcam 
(Cambridge, MA). Biotinylated anti-human IgE monoclonal antibody was from Miltenyi Biotec GmbH 
(Bergisch Gladbach, Germany). Human tumor necrosis factor α (TNF-α) was from Gibco Life Technologies 
Ltd. (Grand Island, NY). Human high-affinity immunoglobulin epsilon receptor subunit α (FcεRIα) was 
from Sino Biological Inc. (Beijing, China). Streptavidin-labeled horseradish peroxidase (Avidin-HRP) was 
from Thermo Fisher Scientific (Waltham, MA). 3,3',5,5'-Tetramethylbenzidine (TMB) was from KPL 
(Gennep, the Netherlands). Human IgG1 Therapeutic EIA Kit was from Cayman Chemical Co. (Ann Arbor, 
MI). Sucrose was from Dai-Nippon Meiji Sugar Co., Ltd. (Tokyo, Japan). L-Histidine hydrochloride was 
from Mitsubishi Tanabe Pharma Co. (Osaka, Japan). L-Histidine was from Kyowa Hakko Bio Co., Ltd. 
(Tokyo, Japan). Glucose 50% injection was from Terumo Co. (Tokyo Japan). These chemicals were of 
high-quality analytical grade and were used as received. 
 
Preparation of Antibody-Poly(amino acid) Complex and Redissolution 
The procedure of precipitation and redissolution of antibody−polyE1 complex were described as follows 
(Figure 4.2.1). Step 1: The antibody stock solutions containing low (1.0 mg/mL) and high (30 mg/mL) 
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concentration antibodies in 10 mM buffer (MOPS at pH 6.5, for adalimumab; citrate at pH 5.5 for 
omalizumab) were prepared. Step 2: Aliquots of 200 µL of various concentrations of polyE1 in 10 mM 
buffer (MOPS at pH 6.5, for adalimumab; citrate at pH 5.5 for omalizumab) were mixed with aliquots of 200 
µL antibody stock solution in same buffer. Step 3: the samples of antibody−polyE mixture were centrifuged 
at 1000 × g for 3 minutes at 25oC. Step 4: The supernatant of 370 µL was removed and precipitates were 
resuspended by vortexing. The nominal value of the samples was 30 µL. Step 5: 10 µL of 600 mM NaCl in 
10 mM buffer was added. The concentrations of antibodies for each step were determined from the 
absorbance at 280 nm using a spectrometer (SpectraMax Plus384; Molecular Devices Co., Ltd., Sunnyvale, 
CA). The immnoreactivity, secondary structure, and aggregation ratio were determined as described below. 
In addition to the above original scale experiments (400 µL), both 50-fold scale up (20 mL; medium 
scale) and 2500-fold scale up (1.0 L; large scale) experiments were performed. Table 4.2.3 shows the 
volumes of these scales at Step 2. A concentration of 0.2 mg/mL polyE1 solution was mixed with 2.0 mg/mL 
adalimumab solution, and then precipitation–redissolution procedures were performed as described above. It 
is note that the final concentration of antibody at Step 5 is five times higher than that at Step 1. The 
containers and centrifuges used for each scale were 1.5 mL centrifuge tubes (MS-4215M; Sumitomo 
Bakelite Co., Ltd., Tokyo, Japan) and Kubota 3740 for mini-scale, 50 mL centrifuge tubes (430829; Corning 
Inc., Corning, NY) and Kubota 5220 for medium-scale, and 1 L Nalgene Polycarbonate Centrifuge Bottles 
(3122-1010; Thermo Fisher Scientific Inc., Waltham, MA) and Kubota 9900 for large-scale. All centrifuges 
were purchased from Kubota Co. (Tokyo, Japan). 
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Concentration of Antibody Solutions by Several Methods 
To compare the efficiencies of the concentration methods, 150 mg/mL omalizumab and adalimumab 
solutions were prepared by the following methods. i) Precipitation–redissolution: 250 µL of 0.15 mg/mL 
polyE1 in 10 mM buffer (MOPS, pH 6.5, for adalimumab; citrate, pH 5.5 for omalizumab) and 250 µL of 30 
mg/mL antibodies in same buffer. The samples of antibody−polyE mixture were centrifuged at 1000 × g for 
3 minutes at 25oC. 462.5 µL of supernatant was removed 37.5 µL of 600 mM NaCl in 10 mM buffer was 
added. The final volume of the concentrated antibodies was 50 µL. ii) Lyophilization−redissolution: 250 µL 
of 30 mg/mL antibodies in 10 mM buffer were added to vials and lyophilized by vacuum freeze-drying 
(Drying Chamber DRC-1100; Tokyo Rikakikai Co., Ltd., Tokyo, Japan). After lyophylization, 50 µL of 10 
mM buffer were added to the vials to redissolve the lyophilized cakes. iii) Evaporation−redissolution: 250 
µL of 30 mg/mL antibodies in 10 mM buffer were added to tubes and evaporated in a rotatory evaporator 
(Centrifugal vaporizer CVE-100D; Tokyo Rikakikai). After evaporation,  50 µL of 10 mM buffer were 
added to the tube to redissolve the cakes. iv) Ultrafiltration: 250 µL of 30 mg/mL antibodies in 10 mM 
 
Figure 4.2.1. Outline of the precipitation–redissolution method for antibody drugs. Aliquots of 200 µL of polyE 
solution in 10 mM buffer were added to 200 µL of stock solution containing low (1.0 mg/mL) or high (30 mg/mL) 
concentration of antibody in the same buffer (Step 1), and antibody–polyE complex suspension was formed 
immediately (Step 2). After centrifugation (Step 3), 370 µL of supernatant was removed and the precipitate was 
resuspended by pipetting or vortexing (Step 4) followed by addition of buffer containing NaCl (Step 5). 
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buffer were put into an ultrafiltration unit with a 50 kDa cut-off (UFC5050; Millipore Co., Ltd., Billerica, 
MA) and centrifuged at 14000 × g at 4°C until the volume was decreased to 50 µL. The time required, final 
concentration, and aggregation ratio were determined as described below. 
 
Immunoassay 
The immunoreactivities of omalizumab were measured by competitive enzyme-linked immunosorbent assay 
(ELISA) to confirm structural integrity of redissolved antibody. Two types of omalizumab with or without 
precipitation−redissolution method were used, as described above. The wells of 96-well ELISA microplates 
(Sumitomo Bakelite Co., Ltd., Tokyo, Japan) were coated with human FcεRIα, and the plates were incubated 
at 4°C overnight. The wells were washed a total of five times by addition of washing buffer containing 24.8 
mM Tris, 136.9 mM NaCl, 2.7 mM KCl, and 0.1% polysorbate 20 (pH 7.4). The wells were then blocked 
with Blocking One at room temperature for 1 hour. After washing of the wells, solutions containing human 
IgE at a constant concentration and omalizumab of different concentrations were added to the wells and 
incubated at room temperature for 1 hour. After washing of the wells, 100 µL of biotinylated anti-human IgE 
monoclonal antibody was added to each well and plates were incubated at room temperature for 1 hour. 
After washing of the wells, 100 µL of streptavidin-labeled horseradish peroxidase was added to each well 
and plates were incubated at room temperature for 30 minutes. After washing of the wells, 100 µL of TMB 
was added to each well and plates were incubated at room temperature for more than 15 minutes. Finally, 
100 µL of 0.1% HCl was added and the absorbance at 450 nm was determined using a microplate reader 
(SpectraMax Plus384; Molecular Devices). 
The immunoreactivities of adalimumab were measured by ELISA. Two types of adalimumab with or 
without precipitation−redissolution method were used, as described above. The wells of polystyrene 96-well 
ELISA microplates were coated with human TNF-α, and the plates were incubated at 4°C overnight. After 
washing of the wells, Blocking One were added and plates were incubated at room temperature for 1 hour. 
After washing of the wells, 100 µL of adalimumab solutions with or without precipitation−redissolution 
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process of different concentrations were added to the wells and plates were incubated at room temperature 
for 1 hour. After washing of the wells, 100 µL of biotinylated anti-human IgG monoclonal antibody was 
added to each well and plates were incubated at room temperature for 1 hour. Subsequent procedures were as 
described above. 
 
Circular Dichroism 
Circular dichroism (CD) experiments were performed using a spectropolarimeter (J-720; Japan 
Spectroscopic Co., Ltd., Tokyo, Japan). Two types of antibodies with or without precipitation−redissolution 
method were used, as described above. The samples containing 1.0 mg/mL antibodies in 10 mM buffer were 
added to a 1-mm path length quartz cuvette, and then CD spectra of antibodies were measured at 25°C. 
Scans were taken from 195 to 250 nm at a rate of 100 nm/min with a sample interval of 0.2 nm, 0.25 s 
response, and 1.0 nm bandwidth. 50 scans were averaged. Obtained far-UV CD spectra were plotted in the 
wavelength range of 210 – 250 nm because of the large noise below 210 nm. The CD spectra of the samples 
were corrected by subtracting the corresponding spectra of the buffers in the absence of antibodies. 
 
Size Exclusion Chromatography (SEC) 
Two types of antibodies with or without precipitation−redissolution method were used, as described above. 
The samples containing 1.0 mg/mL antibodies in 10 mM buffer were centrifuged at 14000 × g for 10 minutes, 
and then the supernatant was analyzed by SEC mode HPLC. The analysis was performed on an SEC column 
(Yarra 3u SEC-3000; Phenomenex Inc., Torrance, CA) on the HPLC system (LC-20A; Shimadzu Corp., 
Kyoto, Japan) at a constant flow rate of 0.5 mL/min. The mobile phase consisted of 100 mM sodium 
phosphate buffer and 0.5 M NaCl (pH 6.8). 
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General toxicity test 
General toxicity tests were evaluated using two types of samples, IgG–polyE2 complex formulation and 
conventional IgG formulation as a control. Each formulation was prepared as described below. IgG−polyE2 
complex formulation: Aliquots of 4.5 mL of 0.24 mg/mL polyE2, 8.0% glucose, and 10 mM citrate (pH 5.0) 
were added to 4.5 mL of 2.0 mg/mL IgG and 10 mM citrate (pH 5.0) aseptically. The samples of 
antibody−polyE mixture were centrifuged at 1000 × g for 3 minutes at 25°C. 8.1 mL of supernatant was 
removed and precipitates were resuspended by vortexing. The nominal value of the samples was 900 µL 
containing 10 mg/mL IgG, 1.2 mg/mL polyE2, 4.0 % glucose, 10 mM citrate (pH 5.0). Conventional IgG 
formulation: Aliquots of 500 µL of 10 mg/mL IgG, 4.0 % glucose, 10 mM citrate (pH 5.0) was prepared. 
Five-week-old Crl:CD (SD) rats were from Charles River Laboratories Japan, Inc. (Kanagawa, 
Japan). The samples were injected subcutaneously into the backs of six rats in two groups at 50 mg/kg (333 
nmol/kg). The body weights of the rat were measured for 0 – 14 days. Weight checks of the organs (heart, 
lung, liver, spleen, and kidney), pathology assessment, and blood test were performed for 1 and 2 weeks after 
injection. In the pathology assessment, the above organs and administration site were assessed. In the blood 
test, the following items were measured: white blood cell count (WBC), red blood cell count (RBC), 
hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration (MCHC), platelets (PLT), activated partial 
thromboplastin time (APTT), prothrombin time (PT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), lactase dehydrogenase (LDH), total bilirubin (TB), 
total protein (TP), albumin (ALB), total cholesterol (TC), triglyceride (TG), phospholipid (PL), glucose 
(GLC), blood urea nitrogen (BUN), creatinine (CRE), inorganic phosphorus (Pi), calcium (Ca), sodium (Na), 
potassium (K), and chlorine (Cl). 
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Pharmacokinetic Profile 
Pharmacokinetic studies were evaluated using two types of samples, omalizumab−polyE2 complex 
formulation and conventional omalizumab formulation as a control. Each formulation was prepared as 
described below. Omalizumab−polyE2 complex formulation: Aliquots of 2.5 mL of 0.24 mg/mL polyE2, 
8.0% glucose, and 20 mM citrate (pH 5.5) were added to 2.5 mL of 2.0 mg/mL omalizumab and 20 mM 
citrate (pH 5.5) aseptically. The samples of antibody−polyE mixture were centrifuged at 1000 × g for 3 
minutes at 25°C. 4.5 mL of supernatant was removed and precipitates were resuspended by vortexing. The 
nominal value of the samples was 500 µL containing 10 mg/mL omalizumab, 1.2 mg/mL polyE2, 4.0 % 
glucose, 20 mM citrate (pH 5.5). Conventional omalizumab formulation: Aliquots of 500 µL of 10 mg/mL 
omalizumab, 10.4% sucrose, 0.20% L-histidine hydrochloride, 0.13% L-histidine, and 0.04% polysorbate 20 
was prepared. Sterile syringes were filled with the samples. Each sample, conventional, and complex 
formulation of omalizumab was injected subcutaneously into the backs of three rats at 10 mg/kg (66.7 
nmol/kg), and the animals were kept in cages for 0 – 22 days. Blood was collected from the tail vein at 0 – 
22 days after injection. Finally, blood concentration of omalizumab was measured using a Human IgG1 
Therapeutic EIA Kit (Cayman Chemical Co., Ann Arbor, MI). All animal experiments were approved by the 
institutional animal care and use committee of Terumo Corp. before the experiments. 
 
 
4.2.3. Results 
Preparation of High-concentration Antibody Solution by Precipitation-redissolution Method 
Previously, our group reported a precipitation–redissolution method using poly(amino acid), which enables 
the preparation of salt-dissociable precipitates of protein–poly(amino acid) complexes [20]. To evaluate the 
efficiency of antibody concentration by the precipitation–redissolution method, two antibody drugs: 
adalimumab (pI = 8.7; for autoimmune disease) and omalizumab (pI =7.6; for allergic asthma), were selected. 
Anionic poly-L-glutamic acid with average molecular weight of 3000 – 15000 Da (polyE1) was selected for 
 
100 
cationic antibodies at pH 5.5 – 6.5, because protein–poly(amino acid) complexes were formed only when 
poly(amino acid) had a charge complementary to that of the protein at experimental pH. Two types of stock 
solution containing low (1.0 mg/mL) or high (30 mg/mL) concentrations of antibodies were mixed with the 
polyE1 solutions. The yield of antibody under the milder condition (1,000 g for 3 minutes at 25oC) was 
identical to that under the harder condition (15,000 g for 20 minutes at 25oC). Thus, the centrifugation 
condition was selected at 1,000 g for 3 minutes at 25oC in this study. Figure 4.2.2 shows the final 
concentration of antibodies at Step 5. In Figure 4.2.1A, final concentration of antibodies increased sharply 
with increasing concentration of polyE1, and reached a plateau at around 0.05 eq., which was consistent with 
the previous report [20]. Similar profiles were observed even at high concentration of stock solution (Figure 
4.2.2B); final concentration values of omalizumab and adalimumab reached about 150 mg/mL at 0.05 eq. 
The yields of these antibodies were also about 100% even at high protein concentration (150 mg/mL) as well 
as low concentration (5 mg/mL). 
 
 
 
 
Figure 4.2.2. Precipitation–redissolution profiles of antibodies by polyE1. Various concentrations of polyE1 were 
added to stock solutions containing 1.0 mg/mL (low) (A) or 30 mg/mL (high) (B) antibodyes in 10 mM buffer. The 
final concentrations of antibodies at Step 5 in the presence of polyE1 were measured. The final concentration of 
antibodies in the absence of polyE1 was lower than that of stock solution due to the dilution of 
precipitation–redissolution process. Closed circles, omalizumab; open circles, adalimumab. 
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Subsequently, the activity and structure of the redissolved antibodies were characterized. As shown 
in Figures 4.2.2A and 4.2.2B, the immunoreactivities of redissolved omalizumab and adalimumab were 
identical to those of native antibodies; the 50% inhibitory concentration values (IC50) of omalizumab and the 
50% effective concentration values (EC50) of adalimumab were equivalent to those without polyE1 (Table 
4.2.1, Figure 4.2.3A,B). Thus, the activities of the antibodies were not altered by the concentration and 
redissolution process. In addition, far-UV circular dichroism (CD) spectra of redissolved antibodies were 
identical to those of the native antibodies (Figure 4.2.3C,D), although slight changes were observed in the 
far-UV CD spectra of adalimumab at 218 nm. These results suggested that the secondary structure of the 
antibodies were significantly maintained even in the redissolved state. Furthermore, SEC analysis indicated 
that the soluble aggregates were not increased in the redissolved antibody solutions (Figure 4.2.3E,F). These 
results suggested that redissolved antibodies retained the original activity, structure, and aggregation 
properties. 
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Table 4.2.1. Immunoreactivities of redissolved antibodies. 
Antibody Concentration Activitycontrol ActivityStep5 
Omalizumab Low 3.99 (nM) a 3.92 (nM) a 
 
High 
 
3.77 (nM) a 
Adalimumab Low 327 (pM) b 321 (nM) b 
 
High 
 
309 (pM) b 
a 50% inhibitory concentration. 
b 50% effective concentration. 
 
Figure 4.2.3. Characterization of omalizumab (A,C,E) and adalimumab (B,D,F) with or witout 
precipitation−redissolution method. (A,B) Binding curve of antibodies. dashed lines; native antibodies, open 
circles; low-concentration redissolved antibodies and closed circles; high-concentration redissolved antibodies. 
(C,D) Far-UV CD spectra of antibodies. solid lines; native antibodies and dushed lines; high-concentration 
redissolved antibodies. (E,F) SEC chromatograms of antibodies, solid lines; native antibodies, dotted lines; 
low-concentration redissolved antibodies ans dushed lines; high-concentration redissolved antibodies, arrowhead; 
monomer peak and arrow; aggregate peak. 
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Feasibility Studies of Precipitation-redissolution Method 
The feasibility studies of the precipitation–redissolution method using poly(amino acid) were performed to 
confirm its utility for pharmaceutical applications. First, the efficiency of the precipitation–redissolution 
method was compared to three conventional concentration methods, i.e., lyophilization–redissolution, 
evaporation–redissolution, and ultrafiltration. As expected, 150 mg/mL antibody solutions were obtained by 
the precipitation–redissolution method (Table 4.2.2). On the other hand, the final concentrations of antibody 
solutions obtained by the conventional methods were 72.7 – 136 mg/mL, suggesting that some antibody was 
lost in the concentration process in these methods. The time required for the precipitation–redissolution 
method was about 2 hours, which was shorter than those of lyophilization and evaporation (Table 4.2.2). 
Furthermore, SEC analysis revealed that soluble aggregates did not increase in the concentrated antibody 
solutions prepared by the precipitation–redissolution method and ultrafiltration, but increased in those 
prepared by lyophilization and evaporation (Table 4.2.2). These results suggested that the 
precipitation–redissolution method is a good alternative to the well-known concentration methods. 
 
 
Table 4.2.2. Comparison of the precipitation–redissolution method with conventional concentration methods. 
    Adalimumab Omalizumab 
 
Time Required 
Final 
concentration 
Aggregation peak 
ratio 
Final 
concentration 
Aggregation peak 
ratio 
Concentration method (hours) (mg/mL) (%) (mg/mL) (%) 
Precipitation-redissolution 2 151 9.67 154 3.98 
Lyophilization-redissolution 18 136 12.7 86.0 7.35 
Evapolation-redissolution 5 133 19.4 96.1 8.61 
Ultrafiltration 2 131 7.29 72.7 3.58 
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To examine whether the precipitation–redissolution method could be scaled up, 10 mg/mL 
adalimumab solutions from 2.0 mg/mL adalimumab were prepared by the addition of 0.1 mg/mL polyE1 at 
three different scales−original-scale (400 µL), 50-fold scale up (20 mL; medium-scale), and 2500-fold scale 
up (1.0 L; large-scale). Similar to the original-scale, the adalimumab–polyE mixed solution formed a 
complex and was suspended immediately at the medium- (data not shown) and large-scales (Figure 4.2.3 
Step 2) At the large scale, the complex was spontaneously precipitated almost completely in 2 hours at Step 
2. After centrifugation (Step 3), the supernatant was removed and resuspended by mild agitation (Step 4). 
Finally, the suspension was fully dissolved by the addition of NaCl in the same buffer (Step 5). ELISA and 
SEC analysis revealed that the immunoreactivities and the amounts of soluble aggregates of redissolved 
adalimumab at medium and large scales were similar to those at the original-scale (Table 4.2.3), suggesting 
that the properties of redissolved antibody were independent of the scale. Thus, it was indicated that the 
precipitation–redissolution method could be scaled up by 2500-fold. 
Table 4.2.3. Scaling up of the precipitation–redissolution method for preparation of 10 mg/mL adalimumab from 2.0 
mg/mL stock solution 
Scale Final concentration Immnoreactivity Aggregates peak ratio 
  (mg/mL) (pM) (%) 
Mini (400 µL) 10.2 302 8.09 
Medium (20 mL) 10.1 317 8.42 
Large (1.0 L) 10.4 289 8.52 
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Finally, to test the potential of antibody–poly(amino acid) complexes for medicinal use, general 
toxicity tests of the antibody–poly(amino acid) complex suspension (Step 4) were performed. Anionic 
poly-L-glutamic acid with average molecular weight of 50000 – 100000 Da (polyE2) was selected because it 
was speculated that poly(amino acids) with larger molecular weight would have longer blood half-lives and 
stronger influence [30]. In addition, rat IgG (pI ≈ 7.0) was selected to avoid immune reaction in rats. 
Suspensions of the complex containing 10 mg/mL rat IgG and 1.2 mg/mL polyE2 (Step 4) were prepared by 
the precipitation–redissolution method, and then injected subcutaneously into rats at 50 mg/kg (333 nmol/kg). 
Comparison of administration of conventional IgG formulation and IgG–polyE2 complex formulation 
 
Figure 4.2.4. Outline of precipitation–redissolution method for adalimumab at the scale of 1.0 L. Aliquots of 0.5 L 
of 0.2 mg/mL polyE1 solution in 10 mM MOPS (pH 6.5) was added to 0.5 L of stock solution containing 2.0 mg/mL 
adalimumab in the same buffer (Step 1), and antibody–polyE complex suspension was formed immediately (Step 2). 
After centrifugation (Step 3), 0.91 L of supernatant was removed and the precipitate was resuspended by mild 
agitation (Step 4) followed by addition of 0.01 L buffer containing NaCl (Step 5). 
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indicated no significant difference in rat body weight or the weights of several organs (heart, lung, liver, 
spleen, and kidney) between the two groups (Figure 4.2.4A,B). In addition, no significant differences in 
pathological findings or blood composition were observed between the two groups (data not shown). These 
results suggested that antibody–polyE complexes did not have general toxicity in these experimental animals. 
Furthermore, pharmacokinetic analysis were performed to compare the behaviors of the conventional 
omalizumab and omalizumab–polyE2 complex formulation in blood. Figure 4.2.4C shows the plasma 
concentration of omalizumab–time curve in rats after subcutaneous administration. The curve of 
omalizumab–polyE2 complex (Step 4) corresponded to that of the conventional omalizumab. These results 
indicated that the antibody–polyE complex formulation did not affect the bioavailability of the therapeutic 
antibody. 
 
 
Figure 4.2.5. General toxicity tests in rats; body weight of rats (A) and weight of organs (B). Conventional IgG 
formulation, closed symbols; IgG-polyE2 complex fomulation, open symbols. (C) Plasma concentration of 
omalizumab–time curve in rats after subcutaneous administration. Conventional omalizumab formulation, open 
circles; omalizumab–polyE2 complex formulation, closed circles. 
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4.2.4. Discussion 
High-concentration (> 100 mg/mL) antibody formulations are indispensable for subcutaneous administration 
because of the limitation of injection volume (typically 1.5 mL) [9, 10]. As demonstrated above, 150 mg/mL 
antibody formulations were successfully prepared from 30 mg/mL antibody solutions using the 
precipitation–redissolution method with poly(amino acid) (Figure 4.2.2). It is emphasized that the procedures 
involved in the precipitation–redissolution method are quite simple: (i) polyE is added to the antibody 
solution, resulting in precipitation of the antibody–polyE complex; (ii) the antibody–polyE precipitates can 
be suspended easily; (iii) the antibody–polyE complexes can be redissolved with saline solution. Note that 
the protein concentration was changed from 1.0 mg/mL to 30 mg/mL, indicating that the 
precipitation–redissolution method could be used for preparation of desirable concentrations of antibody 
formulations. In addition, the precipitation–redissolution method would be applicable for several types of 
therapeutic protein, including enzymes, antibodies, and peptide hormones [20]. 
It is possible that quality of redissolved antibody formulation is comparable to the conventional 
antibody formulation. ELISA revealed that the immunoreactivity of redissolved antibodies was similar to 
that of native antibodies (Table 4.2.1, Figure 4.2.3A,B). Far-UV CD spectra suggested that the secondary 
structure of antibodies did not significantly change by the precipitation−redissolution process (Figure 
4.2.3C,D). In addition, SEC analysis showed that soluble aggregates of redissolved antibodies were similar 
to those of native antibodies (Figure 4.2.3E,F). Furthermore, pharmacokinetic profile of omalizumab/polyE 
complex formulation was similar to that of conventional omalizumab formulation (Figure 4.2.5C). Although 
further investigation of structural and colloidal properties remains unclear, these in vitro and in vivo 
evaluations supported that the redissolved antibodies are likely to be applicable for protein therapy. 
Comparison with conventional concentration methods indicated significant advantages of the 
precipitation–redissolution method with regard to time required and yield (Table 4.2.2). The 
precipitation–redissolution method successfully prepared antibody solutions of about 150 mg/mL within 2 
hours, whereas lyophilization–redissolution, evaporation–redissolution, and ultrafiltration failed to reach this 
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concentration (Table 4.2.2). Although visible aggregates were not observed in the adalimumab concentrated 
by the conventional methods, the final concentrations were lower than 150 mg/mL. The loss of adalimumab 
in these methods were due to the unfavorable influences of these processes, such as adsorption to the 
container or ultrafiltration membrane [31–34] or the generation of water-ice crystals at the periphery of the 
container [35]. The final concentrations of omalizumab obtained by the conventional methods were 
significantly lower than that achieved by the precipitation–redissolution method (Table 4.2.2), which may 
have been due to the instability of omalizumab compared to adalimumab. Indeed, visible aggregates were 
observed in the omalizumab solution during the concentration process, suggesting that the aggregates 
decreased the yield of concentrated omalizumab. Thus, the precipitation–redissolution method enables 
prompt and successful concentration of antibodies without soluble aggregates. 
The precipitation–redissolution method has another significant advantage with regard to scalability. 
The adalimumab solutions with different volume scale were successfully concentrated 5-fold without loss of 
quality (Table 4.2.3). Interestingly, centrifugation is not always necessary to prepare highly concentrated 
antibody formulations on a large scale. As shown in Figure 4.2.4, the adalimumab–polyE complex was 
formed and the solution was suspended immediately. The suspension began to precipitate spontaneously a 
few minutes later and precipitated almost completely within 2 hours (Step 2). The supernatant of the 
precipitation solution without centrifugation did not contain any antibody (data not shown). The volume of 
supernatant collected was 0.98 L, meaning that the theoretical maximum concentration of redissolved 
adalimumab was > 5-fold even without centrifugation. This is important for the application of the 
precipitation–redissolution method for industrialization, e.g., to reduce the costs associated with centrifuges. 
Poly(amino acids) are not listed on the Inactive Ingredient Search for Approved Drug Products of the 
US Food and Drug Administration, although poly(amino acids) have been used as biocompatible materials 
[36–39]. Nevertheless, in vivo tests revealed that the general toxicity and pharmacokinetic profile of the 
antibody–polyE complex formulations were identical to those of the conventional antibody formulation 
(Figure 4.2.5). The antibody–polyE complex could be easily dissociated by saline solution; the salts at 
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physiological ionic concentration (150 mM) shielded the electrostatic interaction between antibody and 
polyE and then dissociated the precipitable complexes [28, 29]. Accordingly, it was suggested that the 
suspension of antibody–polyE complex injected into rats was immediately dissolved to antibody and polyE 
at physiological ionic strength in the subdermal space. Therefore, it was suggested that the 
high-concentration antibody–poly(amino acid) complex has biocompatibility for application in protein 
therapy. 
In summary, this study indicated the feasibility of the precipitation–redissolution method for 
preparation of antibody–poly(amino acid) complex formulations. This simple, quick, and scalable method 
allows the formation of high-concentration protein solutions without loss of structure or function. More 
importantly, antibody–polyE complex formulations have the same level of biocompatibility as conventional 
antibody formulations. Due to its several advantages, the precipitation–redissolution method could be 
beneficial in medical applications. It is expected that protein–poly(amino acid) complex formulations 
prepared by this method could be used in protein therapy. 
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Chapter 5. General Discussion 
 
Proteins are useful materials for various applications in biotechnology and biomedicine. 
Protein-polyelectrolyte complexes (PPC) have a great potential for expanding the applications of proteins. 
Although there have been several fundamental and practical studies of PPC, practical techniques related to 
protein handling have remained insufficient. Here, various techniques were developed using which enable to 
improve conventional protein handling techniques. A general discussion, paerspectives, and future directions 
of this research are presented below. 
 
1.  PEGylated polyelectrolytes 
PEGylated polyelectrolytes are composed of ionic polyelectrolyte segments and non-ionic PEG segments. 
The polyelectrolyte segments can bind to the protein surface through electrostatic interactions, whereas PEG 
provides a steric stabilizing effect due to its strong hydration and high conformational flexibility. Taking 
advantage of these properties, on/off switching of enzyme activity (Chapter 2.1) and stabilization of protein 
against stress (Chapter 2.2) were achieved using PEGylated polyelectrolyte. The common point of these 
results is the formation of soluble PPC. The soluble PPC with PEGylated polyelectrolyte is primarily 
attributed with to the steric repulsion effect of the PEG segment in PEGylated polyelectrolyte. In fact, PPC 
with non-PEGylated polyelectrolyte (i.e., PAA or PAMA) aggregated, resulting in failure of on/off switching 
and stabilization of proteins. Accordingly, PEGylated polyelectrolyte is a new candidate for functionalization 
and stabilization of proteins. 
Interestingly, the formation of soluble PPC with ASNase/PEG-b-PAMA did not affect the enzyme 
activity, whereas α-amylase and β-galactosidase were inactivated. Taking account of not only 
enzyme-polyelectrolyte but also substrate, this difference may have been due to the following properties: (i) 
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the molecular weight (Mw) of the ASNase substrate is smaller than those of α-amylase and β-galactosidase 
substrates [ASNase, L-asparagine (Mw = 132.1 g/mol); α-amylase, p-nitrophenyl-α-D-maltoside (PNPM, Mw 
= 463.3 g/mol); β-galactosidase, o-nitrophenyl-β-D -galactopyranoside (ONPG, Mw = 271.2 g/mol)]; (ii) 
PNPM and ONPG have dye molecules released by substrate, whereas L-asparagine do not; (iii) the surface 
distribution of charged amino acid on the proteins; and (iv) the affinity between the proteins and their 
substrate. Although it is difficult to further discuss the detailed mechanism of inactivation of proteins by 
polyelectrolyte, soluble PPC with PEGylated polyelectrolyte may be applied on a case-by-case basis, e.g., 
drug delivery systems or biosensors. 
 
2.  Enzyme hyperactivation phenomenon 
Enzyme hyperactivation occurred in the presence of not only polyelectrolyte with high Mw (Chapter 3.1), but 
also charged molecules with low Mw, including polyamine (Chapter 3.2). These results suggested that the 
combination of complementary charged pair between molecules and substrates is a key factor in this 
phenomenon. In fact, preliminary experiments indicated that subtilisin activity toward anionic substrates 
increased with the addition of cationic polyelectrolyte. Another interesting point is that cationic ChT was 
hyperactivated not only by the addition of both anionic and cationic polyelectrolytes, suggesting that the 
formation of PPC is not important for the enzyme hyperactivation phenomenon. It should be noted that 
enzyme hyperactivation phenomenon does not require laborious mutagenesis or chemical modification of 
enzymes, and may expand the potential use of enzymes in biotechnological applications as biosensors and 
bioreactors. 
Unfortunately, the detailed mechanism underlying the enzyme hyperactivation phenomenon 
remains unclear. In particular, the enhancement of ChT activity by cationic polyelectrolytes is difficult to 
explain because theoretically cationic polyelectrolyte does not form a PPC with cationic ChT. However, 
molecular dynamics simulation showed that cationic amine compounds bound to the ChT surface, suggesting 
that cationic polyelectrolyte may interact with the ChT surface through not only electrostatic but also 
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hydrophobic interactions. The interaction between enzyme and polyelectrolyte may contribute to the 
accumulation of charged substrate, which is attracted by polyelectrolyte on the enzyme through electrostatic 
interaction. Furthermore, preliminary experiments indicated that hyperactivation of different enzymes, such 
as elastase and trypsin, did not occur despite the presence of complementary charged substrate and 
polyelectrolyte, suggesting that there may be other systematic rules. Thus, further studies are required to gain 
a fundamental understanding of the enzyme hyperactivation phenomenon. 
 
3.  Precipitation-redissolution method 
In contrast to the above studies associated with soluble PPC, there have been few investigation regarding use 
of insoluble PPC. To extend the possibility of using insoluble PPC, a precipitation-redissolution method was 
developed using poly(amino acid) for formulation of high-concentration therapeutic protein. Insoluble PPCs 
with ten types of therapeutic proteins were obtained by screening experimental conditions, and then 
precipitated by centrifugation. The precipitate of insoluble PPC was redissolved by exchanging solvent 
containing saline due to the electrostatic shield by increasing ionic strength. The redissolved proteins had 
native structures and functions, and did not form undesirable aggregates. Furthermore, in vivo experiments 
indicated that the general toxicity and pharmacokinetic profiles of redissolved antibodies corresponded to 
those of a conventional antibody formulation. Therefore, the protein formulation produced by the 
precipitation-redissolution method would be applicable for biomedical use. 
In general, protein precipitation has attracted little attention as a general formulation method. 
However, these data indicate that PPC precipitation is superior as a novel method for concentration of 
protein formulations. In addition, the PPC precipitate stabilized protein against several types of stress, 
including heat, agitation, and oxidation. Use of the precipitation-redissolution method may facilitate use of 
protein precipitation for biomedical applications. 
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Chapter 6. General Conclusion 
 
This thesis described various techniques using protein-polyelectrolyte complexes (PPC) for improvement of 
protein handling. Chapter 2 showed that on/off switching of enzyme activity for large and unstable enzymes 
was possible using PEGylated polyelectrolyte due to the formation of soluble PPC. Based on these findings, 
a stabilizing method designated as non-covalent PEGylation was developed to protect therapeutic 
L-asparaginase against proteolytic degradation and shaking-induced aggregation. These finding indicated that 
soluble PPC with PEGylated complex is applicable to biosensors or drug delivery systems. Chapter 3 
presented an investigation of the enzyme hyperactivation phenomenon, which resulted in a marked increase 
in α-chymotrypsin (ChT) activity by addition of complementary charged pair between substrate and 
polyelectrolyte. In addition, the hyperactivation of ChT using a library of cationic amine compounds with 
different numbers of amine groups and alkyl chains suggested that both of multivalency and hydrophobicity 
of charged compounds were important factors for the enzyme hyperactivation phenomenon. The application 
of enzyme hyperactivation for tumor markers with enzyme activity, such as prostate-specific antigen, may 
facilitate the development of novel sensing methods using enzyme activity as a signal. Chapter 4 showed the 
feasibility of precipitation-redissolution method, which enables the preparation of various types of 
high-concentration protein formulation both easily and quickly. This technique should contribute to the 
development of a novel type of protein formulation, i.e., PPC precipitate formulaton. 
Despite the many fundamental studies regarding PPC, there have been few reports of practical 
techniques using PPC for protein applications. The findings of this study will facilitate the development of 
novel biotechnology and biomedicine applications. For application of the techniques discussed in this thesis, 
a fundamental understanding of the underlying mechanisms is essential, especially the enzyme 
hyperactivation phenomenon. Protein-handling techniques using PPC are likely to be widely adopted in 
various research fields in the near future. 
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